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Introduction: Dietary questionnaire studies have suggested that patients with 
oesophageal adenocarcinoma are deficient in antioxidants. It is unknown whether the 
same holds true for patients with the precursor lesion, Barrett's oesophagus. The 
current study considered the hypothesis that patients with Barrett's oesophagus were 
deficient in antioxidants compared to reflux patients without evidence of Barrett's 
oesophagus.
Bcl-2 is an inhibitor of apoptosis or programmed cell death and bax is a promoter. p53
is a protein regulating these. Studies have shown a bcl-2/bax ratio favouring bax
expression to be predictive of a good response to neoadjuvant chemoradiotherapy;
that expression of mutated p53 is predictive of a poor response.
The current study considered the hypothesis that the ratio of bcl-2/bax and the
expression of p53 in oesophageal tumours could be used to predict the response to
chemoradiotherapy.
Methods: Serum antioxidant profiles (copper, selenium, zinc, vitamins A, C & E, the 
carotenoids, and xanthophyll) were determined for patients with: Barrett's oesophagus 
(n=36), erosive oesophagitis (n=32) and patient controls (n=35).
The expression of bcl-2, bax and p53 in oesophageal tumour biopsies were 
ascertained by means of immunohistocytochemistry, and compared with the patients' 
known response to chemoradiotherapy.
Results: Patients with Barrett's oesophagus had significantly lower levels of 
selenium, vitamin C and |3-cryptoxanthine compared to the other patient groups.
There was no difference demonstrated in the expression of bcl-2, bax, and p53 
between two groups of patients, those responding well, and those responding poorly 
to chemoradiotherapy.
Conclusion: This study confirmed the hypothesis that patients with Barrett's 
oesophagus are deficient in certain antioxidants. It is speculated that antioxidant 
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GLOSSARY OF TERMS
Adenomata: A collection of neoplasms of glandular origin. Adenomas can grow 
from many organs including the colon, adrenal, pituitary, thyroid, etc. These 
neoplasms are benign, but some are known to have the potential, over time, to 
transform to malignancy (at which point they become known as adenocarcinoma).
Adjuvants: These are agents which modify the effect of other agents while having 
few if any direct effects when given by themselves, hi this sense, they are very 
roughly analogous with chemical catalysts.
Cytology may refer to cytopathology, the cellular diagnostics of disease.
Endoscopy: This means looking inside and refers to looking inside the human body 
for medical reasons.
Gastroesophageal Reflux Disease (GORD): Defined as chronic symptoms or 
mucosal damage produced by the abnormal reflux of gastric contents into the 
oesophgus. This is commonly due to transient or permanent changes in the barrier 
between the oesophagus and the stomach. This can be due to incompetence of the 
lower oesophageal sphincter (LOS), also known as the cardiac sphincter, transient 
LOS relaxation, or association with a hiatal hernia.
Helicobacter pylori: A bacterium that infects the gastric mucosa. Many peptic ulcers 
and some types of gastritis are caused by H. pylori infection, although most humans 
who are infected will never develop symptoms. This bacterium lives in the human 
stomach exclusively and is the only known organism that can thrive in that highly 
acidic environment. It is helix-shaped (hence the name helicobacter) and can literally 
screw itself into the mucosa to colonize.
Histology: This is the study of tissue sectioned as a thin slice, using a microscope. It 
can be described as microscopic anatomy.
Leukopaenia: A low white cell count.
Ligand: hi chemistry this is an atom or molecule that donates its electrons, or shares 
its electrons with one or more central atoms or ions.
Thrombocytopenia: The term for a reduced platelet count.
Metaplasia: The replacement of one differentiated cell type with another 
differentiated cell type.
Mitoses: The process of cells dividing. The number of mitoses per high power field 
of a pathological specimen correlates with the rate of cell division, and hence the 
degree of malignancy.






The present thesis consists of the following chapters.
Chapter One: Gives a general introduction to the risk factors involved in
oesophageal cancer both in the initial development and subsequent progression.
Chapter Two: Outlines the published literature relevant to both studies.
Chapter Three: The first study described in this chapter was designed to determine
whether antioxidant levels were lower in subjects with Barrett's oesophagus than in
controls.
Chapter Four: This chapter outlines the second study which examined the
expression of bcl-2, an apoptosis inhibitor, and p-53, an apoptosis regulator, in tumour
specimens and correlated this with the response of that tumour to chemotherapy.
Chapter Five: This final chapter summarises the main findings from each study,
discusses possible areas for further research and finally concludes.
1.2 INTRODUCTION
In recent years a worrying increasing trend in the incidence of oesophageal 
cancer has been noted. In some countries it has more than doubled in the last 20 years 
[1] . This however does not hold true for all types of oesophageal cancer, of which 
there are two main histological types. Squamous cell carcinoma usually occurs in the 
upper two thirds of the oesophagus, and is associated with smoking and alcohol, 
whereas adenocarcinoma of the oesophagus usually occurs in the lower third, and 
almost always arises in an area of Barrett's oesophagus. This is a condition caused by 
acid reflux from the stomach into the lower oesophagus. The normal lining of the 
oesophagus is damaged by the acid, and as it heals it undergoes a histological change, 
from the normal squamous epithelium into an abnormal columnar one. This is the 
same type as lines the stomach. It is the incidence of adenocarcinoma that has 
increased recently, the incidence of squamous cell cancer remaining the same. There 
is no clear evidence as to why there should have been such a dramatic increase, but it 
has been suggested it is due to the increase in obesity, and hence reflux disease [2] .
There have been many dietary studies investigating the relationship between 
diet, and both oesophageal squamous and adenocarcinoma. It has been shown beyond 
doubt that both histological types are more prevalent amongst people who consume a 
diet deficient in fresh fruit and vegetables [3-13]. There is also evidence to attest to 
the protective effects of antioxidants, with supplementation studies showing a 
decrease in the incidence in cancer amongst those patients receiving supplementation 
[14]. It has been shown that antioxidant deficiency is associated with an increased risk 
of progression of Barrett's mucosa to high-grade dysplasia, which is one step below 
adenocarcinoma, and patients with Barrett's oesophagus have been shown to have 
decreased Vitamin C levels both in the blood, and in the Barrett's tissue itself [15]. As
yet there is no published evidence looking at serum trace element levels (Selenium, 
Copper, Zinc) in patients with Barrett's oesophagus, or at the difference in antioxidant 





The oesophagus is a muscular tube lined mostly by squamous mucosa. It 
extends from the pharynx to the cardia of the stomach, and in the adult is 
approximately 25cm long [16]. The lower 2 cm of the oesophagus is situated below 
the diaphragm, and is lined by columnar mucosa of gastric type. The junction between 
the two types of mucosa, the squamocolumnar junction is clearly visible on 
endoscopy, and is usually found at 40cm. This distance is measured from the incisor 
teeth [16].
There are two main histological types of carcinoma of the oesophagus. 
Squamous cell carcinoma, and adenocarcinoma [16]. Squamous cell tumours most 
commonly arise in the squamous epithelium in the upper two thirds of the 
oesophagus, and adenocarcinomas are most commonly found in the lower third. 
Adenocarcinoma arises from columnar mucosa. These tumours will have almost 
invariably developed on the basis of a Barrett's oesophagus [16]. Worldwide most 
carcinomas are squamous cell tumours, with adenocarcinomas accounting for 0.8- 
8.0% of all carcinomas, depending on the local epidemiology [17].
Cigarette smoking and alcohol consumption are important risk factors for 
squamous cell cancer in areas of the world that have a low to moderate risk [17]. A 
study undertaken by Vaughan et al in Seattle in 1995 investigated the use of alcohol 
and cigarettes by patients with both adenocarcinoma, and squamous cell carcinoma 
[18]. Both cigarette smoking, and alcohol consumption were found to be significant 
risk factors for both histological types, although the risk of developing squamous cell 
cancer amongst smokers is far higher than the risk of developing adenocarcinoma. 
Drinking over 21 UK units of alcohol per week was also a risk factor for developing 
squamous cell carcinoma [18].
In the year 2000 the World Health Organisation presented a detailed model to 
estimate cancer survival in different parts of the world. Oesophageal cancer was the 
tenth commonest cancer worldwide, with 386,612 new cases reported [19], and it 
accounted for 6% of all worldwide cancer deaths. It was preceded by lung, breast, 
stomach, colon, and liver, which were the first, second, third, fourth, and fifth 
commonest cancers that year [19]. hi recent years the steadily increasing incidence of 
cancer of the lower oesophagus and upper stomach has been noted [1], in fact in some 
areas of the United States the incidence has doubled over the last 20 years, with 
increases in incidence in men ranging from 4% to 10 % per year. This rate of increase 
exceeded that seen for any other type of human cancer [1].
The incidence of squamous cell carcinoma has remained relatively stable with 
only minor increasing trends noted in Denmark and the Netherlands among men, with 
women demonstrating similar trends in Canada, Switzerland, and Scotland [20]. The 
situation in the United States is the same, with the incidence of squamous cell 
carcinomas remaining relatively constant over the last 15 years [18]. Contrary to this 
the incidence of adenocarcinoma has been rapidly increasing [1, 18]. Time-trends 
incidence of subsite-specific cancers were analysed by Vizcainio et al in order to 
examine the incidence patterns of the two major types of oesophageal cancer [20]. 
Their findings correlate with those above. There was an increase in the incidence of 
oesophageal adenocarcinomas in both sexes in the United States, Canada, South 
Australia, as well as in six European countries [20]. In the South Thames region of 
England there has been no significant change in the incidence rate of upper two-third 
carcinoma of the oesophagus, however lower third carcinoma has shown a marked 
increase for both sexes [21].
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The rate of increase in incidence varies markedly according to region. An 
epidemiological study using information from the U.S. Surveillance Epidemiology, 
and End Results (SEER) cancer registry from the years 1973-1998 has found the rate 
of increased incidence of adenocarcinoma in Seattle to be over twice that of Utah, the 
rates being 800%, and 300% respectively [22]. The rate of increase in incidence of 
adenocarcinoma in Europe (Germany) ranges from 248% in Brandenburg to 432% in 
the Saarland [23]. Although both these papers quoted have not postulated as to why 
there should be such a geographical difference in the observed increase in incidence, 
it has been proposed that variations in the coding, classification and detection of 
gastro-oesophageal malignancy may have contributed partially to the observed trends 
[2]. It is also entirely possible for there to be geographical variation in the factors 
promoting the development of oesophageal carcinoma, namely alcohol, smoking, 
obesity, and diet.
2.2 REASONS FOR INCREASING INCIDENCE
Barrett's oesophagus is a pre-malignant condition, which can give rise to 
adenocarcinoma, and gastro-oesophageal reflux disease is a precursor to Barrett's 
[16]. Factors promoting the development of both have been proposed to explain the 
rising trends discussed above; these include the declining rates of Helicobacter pylori 
infection, obesity and dietary factors [2]. In a Swedish nationwide case control study, 
gastro-oesophageal reflux and obesity were identified as strong and independent risk 
factors for oesophageal adenocarcinoma [24]. With increasing duration and severity 
of reflux symptoms and with increasing body mass index the risk increased in a dose 
dependent manner. When combined, reflux symptoms and obesity entailed greatly 
increased risk estimates. The author proposes possible reasons for the increasing
incidence of adenocarcinoma of the oesophagus, and these include an increase in the 
prevalence of reflux disease, and the increasing prevalence of obesity [24]. A 
Swedish epidemiologic investigation by the same author of the possible association 
between gastro-oesophageal reflux and adenocarcinoma of the oesophagus has 
corroborated these findings [25]. Among persons with recurrent symptoms of reflux, 
as compared with persons without such symptoms, the odds ratios were 7.7 for 
oesophageal adenocarcinoma. The more frequent, more severe, and longer lasting the 
symptoms of reflux the greater the risk. It was found that amongst persons with long- 
standing and severe symptoms the odds ratios were 43.5 for oesophageal 
adenocarcinoma [25].
2.3 BARRETT'S OESOPHAGUS
The major risk factor for the development of adenocarcinoma at the lower 
oesophagus and gastroesophogeal junction is the condition known as Barrett's 
oesophagus [26]. This was named after a British surgeon Norman Rupert Barrett, who 
worked at St Thomas's Hospital, London from where he had graduated in 1928. It is 
postulated that gastric juice refluxes into the lower oesophagus and this can injure the 
oesophageal squamous epithelium. When this injury heals through a metaplastic 
process an abnormal columnar epithelium (the same type as lines the stomach) 
replaces the injured squamous epithelium and this results in the condition of Barrett's 
oesophagus [26].
Damaged lower oesophageal epithelium was first recognised in 1906 by a 
pathologist called Tileston [27], who reported on several patients with peptic ulcer of 
the oesophagus, and the close resemblance of the mucous membrane surrounding the 
ulcer to that normally found in the stomach. It was firstly thought that this was due to
the proximal part of the stomach being tethered in the chest by a congenitally short 
oesophagus and this was supported by Barrett in 1950 [28]. By 1953 it was argued 
that the columnar-lined intrathoracic structure was in fact oesophagus, due to the lack 
of a peritoneal covering and the presence of islands of squamous epithelium and 
submucosal glands [29]. Barrett suggested the condition be called 'lower oesophagus 
lined by columnar epithelium' [30]. It has since been known as Barrett's oesophagus. 
This pre-malignant condition ie Barrett's oesophagus can be recognised at the time of 
upper gastrointestinal endoscopy and confirmed by biopsies of the oesophagus. It is 
found in approximately 12% to 18% of patients undergoing upper endoscopy for 
symptoms of reflux [31, 32]. Modern data indicate that patients with Barrett's 
oesophagus develop oesophageal adenocarcinoma at the rate of 0.5% per year, a rate 
that is more than 30-fold higher than that of the general population [33].
2.4 PROGNOSIS
The prognosis of any patient diagnosed with oesophageal cancer is dismal. In 
one report from Europe (Germany) the five-year survival of all patients with 
oesophageal cancer was less than 10% for the period 1971-1995 [23]. In Northern 
America the median survival is 14.5 months, for those patients receiving maximum 
treatment in the form of surgery and chemoradiotherapy [34]. hi a survey of 
oesophageal and all gastric cancers in Wales only 25% of all patients were alive at 
two years [35]. In a report by the World Health Organisation for the year 2000 the 
global incidence of oesophageal cancer was 386, 612, with a mortality of 350, 841 
[19]. This means that for any given year almost the same number of people die from 
oesophageal cancer as are diagnosed, outlining the poor prognosis.
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The only opportunity of a cure for oesophagastric cancer is surgical resection. 
This is a major procedure which carries a mortality rate of around 8% [36]. In a 
review of 126 patients having a resection for oesophageal carcinoma Mariette et al 
achieved an overall three and five year survival rate of 41% and 25% respectively 
[37]. Thus surgical removal of the tumour offers a much improved overall survival 
rate, but only a very small proportion of patients are eligible for resection. In the 
Welsh survey 33% of patients were able to be treated this way [35], the remainder 
being excluded on the basis of poor physiological reserve, liver metastases and local 
invasion. The majority of patients are inoperable at the time of presentation.
2.5 FACTORS WORSENING PROGNOSIS
There are factors which worsen prognosis in oesophageal cancer. The 
presence of lymph node metastases significantly worsens the patients' prognosis [38]. 
A Japanese study in 2000 assessed the survival of patients having had an oesophageal 
resection and who were found to be lymph node free of metastases at the time of 
operation. The 1, 3, 5, and 10 year survival rates were 86%, 73%, 67%, and 35% 
respectively [39]. A further Japanese study looked at the prognosis of patients with 
zero, one to three, four to seven, and eight or more lymph nodes involved. The 5-year 
survival rates were 53%, 34%, 17%, and 0% respectively [40]. It is obvious that 
patients with fewer metastases have better long term survival, but unfortunately many 
patients present at an advanced stage hence the poor prognosis.
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2.6 NEOADJUVANT THERAPY (NT)
Chemoradiotherapy can be used in the neoadjuvant or palliative setting for 
oesophageal cancer and also theoretically to treat micrometastases (microscopic 
metastases that are not detectable with standard imaging). Currently neoadjuvant 
Chemoradiotherapy is given in an attempt to downsize advanced tumours in order that 
surgical resection may be more successful. The drugs most usually used for 
neoadjuvant therapy are cisplatin plus 5-fluorouracil. These work by inhibiting the 
mitoses of tumour cells. Tumour cells divide much more frequently than normal cells 
in the body and this is why the drugs target them. Unfortunately the drugs also have 
an effect on normal cells in the body, particularly those that divide frequently, such as 
gastrointestinal mucosa, and bone marrow. This accounts for unpleasant side effects. 
These include nausea and vomiting, diarrhoea, leukopaenia, thrombocytopaenia, 
electrolyte imbalance, febrile neutropaenia and mucositis, even death has been 
documented [41]. The drugs are also nephrotoxic. [42]. Furthermore there are also 
complications related to the long-term infusion lines used for the administration of the 
drugs. Most commonly sepsis and line infection occur [43].
Radiotherapy to the oesophageal tumour is given in fractions of 45 Gy, 
administered in 25 fractions over a five-week period, concurrently with the third and 
fourth cycles of chemotherapy [44]. Radiation portals with a five-six cm margin 
above and below the tumour are recommended [45]. This field will inevitably include 
the heart and lungs. Radiotherapy can damage normal tissues, and computed 
tomography frequently demonstrates radiation-related lung damage adjacent to the 
mediastinum [45]. Radiotherapy to the lungs can result in increasing impairment of 
gas exchange [46], and cardiac complications are a particular problem with radiation 
treatments to the mediastinum and breast [47].
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Neoadjuvant therapy (NT) is a difficult area to review. Preoperative 
chemoradiotherapy has been used in an attempt to decrease tumour activity, increase 
resectability rates and improve disease-free and overall survival [48]. The only real 
measure of its worth is post-op survival and this appears to be greater in patients who 
have had a complete histological response to the therapy, namely in whom there are 
no viable tumour cells in the resected specimen. The percentage of patients having a 
complete histological regression to chemoradiation varies, with figures of 15%, [49] 
to 33%, [50] quoted in the literature.
2.7 MANDARD (TUMOUR REGRESSION GRADE)
Mandard et al 1994 carried out a pilot study to determine if pathologic 
assessment of tumour regression correlated with disease-free survival [51]. Semi- 
serial sections of resected specimens from patients treated with pre-operative cisplatin 
and radiotherapy, who then underwent surgery were examined. All specimens were 
allocated a tumour regression grade (TRG). This was quantified as follows: TRG 1 
(complete remission) showed absence of residual cancer with fibrosis extending 
through the different layers of the oesophageal wall. TRG 2 was characterised by the 
presence of rare residual cancer cells scattered through the fibrosis. TRG 3 was 
characterised by an increase in the number of residual cancer cells, but fibrosis still 
predominated. TRG 4 showed residual cancer outgrowing fibrosis, and TRG 5 was 
characterised by absence of regressive changes. 93 consecutively resected specimens 
were examined. Of these 42% were TGR 1-2, 20% were TGR 3, and 33% were TGR 
4-5. After multivariate analysis, only tumour regression (ie TRG 1-3 vs TRG 4-5) 
remained a significant (p<0.001) predictor of disease free survival.
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Conversely a second paper, the research for which was carried out in Ireland, 
examined the TRG in similar patients and found that TRG had no significant effect on 
survival (p=0.06) [52].
2.8 RESPONSE TO NEOADJUVANT THERAPY
In a recently published (2002) Japanese non-randomised study of patients with 
advanced (T4) oesophageal squamous cell cancer it was found that after neoadjuvant 
therapy (NT) and successful surgical resection, the five-year survival rate was 
prolonged significantly in patients particularly those who achieved a complete 
response (71% compared to 32% for a partial response) The remaining 7% of patients 
had no response and the five-year survival rate was 0% [53]. This finding has been 
supported by a European randomised controlled trial, again of patients with 
oesophageal squamous cell cancer. Patients responding to chemoradiotherapy and 
having a surgical resection had significantly better 3 and 5-year survival rates (74% 
and 60%), as compared to non-responders to chemoradiotherapy, who also had a 
surgical resection. (24%, and 12% respectively; p=0.0002) [54]. Walsh et al (1996) 
conducted a prospective, randomised trial comparing surgery alone with combined 
chemotherapy, radiotherapy and surgery. Fifty-five patients with oesophageal 
adenocarcinoma had multimodal therapy, and fifty-five patients, again with 
adenocarcinoma had surgery alone. 42% of patients treated with multimodal therapy 
had positive nodes or metastases as compared with 82% undergoing surgery alone 
(pO.OOl). The median survival of patients assigned to multimodal therapy was 16 
months, as compared with 11 months for those assigned to surgery (p=0.01). At one, 
two, and three years, 52, 37, and 32 percent, respectively of patients assigned to 
multimodal therapy were alive, as compared with 44, 26, and 6 percent of those
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assigned to surgery. The authors concluded that multimodal treatment was superior to 
surgery alone for patients with resectable adeno carcinoma of the oesophagus [55].
The Medical Research Council Oesophageal Cancer Working Group 
conducted a randomised controlled trial comparing surgical resection with or without 
preoperative chemotherapy in oesophageal cancer of any cell type. Clinicians could 
choose to give radiotherapy irrespective of randomisation. This was a large trial with 
802 patients recruited. There were 400 in the chemotherapy and surgery group (CS) 
and 402 in the surgery alone group (S). Median survival was 512 days in the CS 
group compared with 405 days in the S group. Two-year survival rates were 43% in 
the CS group and 34% in the S group. Overall survival was better in the CS group 
(p=0.004). The investigators concluded that two cycles of preoperative cisplatin and 
fluorouracil improve survival without additional serious adverse events in the 
treatment of respectable oesophageal cancer [56].
Urschel [57] conducted a meta-analysis of randomised controlled trials that 
compared neoadjuvant chemoradiation and surgery to surgery alone for resectable 
oesophageal cancer. Nine trials, including 1116 patients were selected. A complete 
pathological response to chemoradiation occurred in 21% of patients. The three-year 
survival benefit was most pronounced when chemotherapy and radiotherapy were 
given concurrently, instead of sequentially. Chemoradiation was also associated with 
a lower rate of oesophageal resection, but a higher rate of complete resection [57].
It is possible preoperatively to determine patients who are likely to have 
achieved a pathological response by measuring the reduction in tumour size with 
endoscopic ultrasound (BUS), post NT. Chak [34] for example reported that patients 
classed as responders on repeat BUS had a median survival of 17.6 months, as 
compared to 14.5 months for non-responders; p=<0.005. Survival was significantly
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longer in responders compared with non-responders in the patient subgroup who 
underwent surgical resection (19.7 months vs. 14.6 months; p=<0.005) [58].
The other area in which NT seems to be effective is in the treatment of locally 
advanced tumours. The survival has been found to be prolonged in squamous cell 
carcinoma node-positive patients with a median survival of 12 months compared to 19 
months, for those patients having resection alone, or resection + NT; p=0.0193 [50] 
and it has also been found to improve survival in T4 tumours, with NT patients having 
a better 5-year survival [59].
2.9 CONCERNS REGARDING NEOADJUVANT THERAPY
There are concerns as to the use of NT. Firstly, is the issue regarding the use 
of the patients' remaining survival time. Some would advocate that the patient would 
be best served by having a comfortable remaining survival time rather than have it 
taken up by NT, with all its attendant side effects, and repeated hospital visits.
Secondly, there have been studies, finding there to be no benefit whatsoever to 
the patient with regards to improving their survival time [48, 58, 60, 61]. Using the 
Cochrane database reviews of 14 randomised controlled trials and one meta-analysis 
of pre-operative chemotherapy versus surgery alone Malthaner concluded that there is 
no strong evidence to recommend pre-operative chemoradiotherapy in the treatment 
of surgically resectable carcinomas of the thoracic oesophagus [48].
A further study carried out in Hong Kong of 83 consecutive squamous cell 
oesophageal cancer patients having NT, followed by surgical resection concluded that 
there was no added benefit in the overall survival of these patients [58]. This 
conclusion has been supported by a paper produced by the Sylvester Comprehensive 
Cancer Center, Miami, Florida [60]. hi this study 72 patients underwent oesophageal
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resection. Patients were divided into three groups according to the type of 
preoperative treatment; group l(n=44) surgery alone; group 2(n=18) neoadjuvant 
5- fluorouracil chemotherapy; group 3(n=9) neoadjuvant 5- fluorouracil based 
chemotherapy, and external beam radiation. One patient received radiotherapy alone. 
It was found that neoadjuvant therapy failed to improve survival rates and 
preoperative chemoradiation was associated with a high perioperative mortality rate. 
Finally, a randomised trial conducted in New York assessed the overall survival of 
patients randomised to chemoradiotherapy and surgery or surgery alone. It was found 
that preoperative chemotherapy with a combination of cisplatin and 5- fluorouracil 
did not improve the overall survival among patients with adenocarcinoma of the 
oesophagus [61].
Lastly, there are concerns as to whether the giving of NT may actually cause 
an increased morbidity and mortality in the post-operative period. Unfortunately it 
may be that if the patients' tumour cells are sensitive to chemotherapy and 
radiotherapy then their normal, healthy tissues may also be sensitive. In other words, 
if a patient responds to treatment they may be at a higher risk of post-operative 
complications. It has been shown that patients who received neoadjuvant therapy had 
a higher rate of pneumonia [59], and they may be susceptible to intractable infections 
[62]. It has also been found to reduce the physical performance of the patient, which 
can be taken as a predictor of the subsequent postoperative risk [63]. However, there 
are other studies, which have found there to be no difference in complication rate [64, 
65]. The previously discussed Medical Research Council Oesophageal Cancer 
Working Group study found there to be no difference in the post-operative 
complications reported in the surgery and chemotherapy group and the surgery alone
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group. Finally NT is expensive and it may be that this is a waste of resource if there is 
no real advantage to the patient by its application.
2.10 bcl-2, bax AND p53
It would obviously be an advantage if it were possible to predict the patients 
who will respond to chemoradiotherapy, as currently only approximately one third of 
patients have an absence of cancer cells histologically. This conversely means that 
two thirds of patients will not have a histological response, having residual cancer 
cells, and could be spared toxic drug regimes unlikely to confer any survival 
advantage. The response to chemoradiotherapy depends on how readily tumour cells 
can be triggered to apoptose.
Apoptosis is defined as an active, physiologic cascade of events, characterised 
by cell shrinkage due to dehydration, nuclear fragmentation, and membrane blebbing 
[66]. Cell death marked by cellular swelling should be called oncosis, whereas the 
term necrosis refers simply to cell death [67]. Apoptosis and oncosis are therefore pre- 
mortal processes [67]. The first microscopic denominations for cell death appeared in 
1879 with the introduction of the terms karyorhexis indicating the disintegration of 
the nucleus, and karyolysis describing the disappearance of the nucleus. In 1885 the 
term chromatolysis was coined to describe the disappearance of the nucleus [67].
Apoptosis is a form of intentional suicide based on a genetic mechanism. It is 
characterised by morphological as well as biochemical criteria [68]. Morphologically 
the cell shrinks, and becomes denser. The chromatin becomes packed into smooth 
masses applied against the nuclear membrane, creating curved profiles that have 
inspired terms such as half-moon, horse-shoe, sickle, and ship-like. The nucleus may 
also break up, and the cell emits processes that often contain nuclear fragments. These
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processes tend to break off and become apoptotic bodies, which may become 
phagocytosed by macrophages or neighbouring cells or remain free. The cell may also 
shrink into a dense rounded mass, as a single apoptotic body [68]. There is little or no 
swelling of mitochondria or other organelles. The DNA is biochemically broken 
down, due to specific cleavage. The process is under genetic control, and can be 
initiated by an internal clock, or by extracellular agents such as hormones, cytokines, 
killer cells, and a variety of chemical, physical, and viral agents [68].
There is a misunderstanding between the terms apoptosis, and programmed 
cell death. Two different scenarios are involved in apoptosis. Firstly a programme to 
carry out suicide, and secondly a programme to trigger suicide. The phenomenon 
properly known as programmed cell death refers to situations in which cells are 
programmed to die at a fixed time. Such is the death on schedule of certain clusters of 
cells in the embryo. For example in the chick embryonic plate, a group of cells has to 
die at a precise time to help create the outline of a wing. These cells die on schedule 
even if they are transplanted elsewhere in the embryo [68].
Ischaemic cell death is characterised by swelling; thus it is defined by a name 
that refers to swelling, ie oncosis [68]. This is a form of cell death accompanied by 
cellular swelling, organelle swelling, blebbing, and increased membrane permeability. 
Its mechanism is based on failure of the ionic pumps of the plasma membrane. It is 
caused typically by ischaemia and possibly by toxic agents that interfere with ATP 
generation or increase the permeability of the plasma membrane. It is usually 
accompanied by karyolysis [68].
Three mechanisms are known to be involved in the apoptotic process; a 
receptor-ligand mediated mechanism, a mitochondrial pathway, and a mechanism in 
which the endoplasmic reticulum plays a central role [67]. All three mechanisms
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activate caspases which are responsible for the characteristic morphological changes 
observed during apoptosis. Apoptosis can be induced by binding of a ligand on a 
specific receptor which is located on the cell membrane. Procaspases are then 
converted into active caspases after the receptor is activated by ligand binding [67]. 
These specific receptors contain a cytoplasmic domain responsible for the signal 
transduction in apoptosis. This domain is called the death domain.
The receptor-ligand mediated apoptotic pathway is not the only mechanism in 
the apoptotic process. Certain cytotoxic agents, such as nitrogen monoxide, and 
radiation, cause apoptosis in another manner involving the mitochondria, and more 
specifically the mitochondrial protein cytochrome c. [67] This is located on the 
outside of the inner mitochondrial membrane, and in the intermembrane space. It has 
an important function in the intracellular electron transport chain reaction for the 
production of ATP. During apoptosis cytochrome c is released in the cytosol. There it 
binds to the apoptosis protease activating factor. These form a complex together, 
activate procaptases and captases leading to the known morphological consequences 
[67].
The release of cytochrome c into the cytosol is regulated by proteins coded by 
genes of the bcl-2 (B-cell lymphoma) family. Bcl-2, and bax are members of this 
family. Bcl-2 is an apoptosis inhibitor which is found in vertebrates, and it is thought 
to inhibit the working of cytochrome c rather than its release [67]. Bax is an apoptosis 
promoter, and does this by releasing cytochmome c, although it is still unclear how it 
achieves this. It is possible that bax and bcl-2 regulate mitochondrial permeability via 
a megachannel which is also called mitochondrial permeability transition pore. This 
channel is built up by proteins of the inner and outer mitochondrial membrane and by 
intermembrane proteins. The opening of this channel results in an influx of ions with
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subsequent swelling of the mitochondrion. This causes breaks in the outer membrane 
while the inner membrane remains intact because it has a larger surface. Cytochrome 
c escapes through the outer membrane breaks and enters in the cytosol [67]. The 
formation of a megachannel also occurs in oncosis/necrosis, but in these latter 
processes the cellular metabolism is already damaged to the extent that activation of 
captases is no longer possible and the cell has no control of its own death mechanism 
[67].
The p53 tumour suppressor gene codes for the p53 protein. This gene is 
mainly expressed when DNA damage occurs by radiation or chemotherapeutics [67]. 
The subsequently produced p53 protein, if present in high amounts, increases the 
number of bax transcripts, and subsequently induces apoptosis [67]. Wild-type p53 
protein also mediates apoptosis by directly activating the expression of bax and by 
indirectly inhibiting the expression of bcl-2 [69, 70].
Apoptosis is an energy dependent process, whereas oncotic cell death is 
independent of captase activation, and occurs subsequent to ATP depletion [71]. 
Intracellular ATP plays an important role in the execution of apoptosis and not of 
oncosis. Furthermore it has been shown that necrosis appears exclusively in the 
presence of total glucose deprivation accompanied by total loss of ATP. Thus it 
appears that oncosis occurs at low to zero ATP levels, and apoptosis can only occur in 
the presence of higher intracellular energy stores [71].
Katada et al, [72] found overexpression of bcl-2 in 72% of Barrett's 
metaplastic lesions and in 100% of Barrett's with low-grade dysplasia. Rioux-Leclerq 
et al [73] also reported loss of bcl-2 expression in Barrett's metaplasia with high 
grade dysplasia. These results suggest two possible explanations. Firstly that 
inhibition of apoptosis by overexpression of bcl-2 occurs early in the dysplasia-
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carcinoma sequence and secondly that dysplastic and cancerous cells are capable of 
evading apoptosis through cellular mechanisms other than those involving bcl-2 
inhibition of apoptosis [72].
There have been studies looking at the expression of p53 in oesophageal 
tumour specimens. It been found to harbour mutations in more than 50% of both 
squamous cell and adenocarcinomas of the oesophagus [74]. Further studies have 
been undertaken to see whether expression of p53 can be used to predict the response 
to chemoradiotherapy. The results of these are somewhat contradictory, with one 
American study concluding that overexpression of p53 is associated with decreased 
responsiveness to induction chemoradiotherapy in patients with oesophageal 
adenocarcinoma, but that no such association exists in patients with oesophogeal 
squamous cell carcinoma [75].
A Japanese study however, assessed the presence of p53 mutation in 40 
patients having chemoradiotherapy for oesophgageal carcinoma and found that 24 
patients had a p53 mutation. 13 patients achieved a complete response to the 
chemoradiotherapy. The survival rate in the 24 patients with p53 mutation did not 
differ significantly from that in the 16 patients without the mutation [76].
A further Japanese paper followed a different approach. Human oesophageal 
tumour cells bearing mutated p53 were retrovirally transduced with wild-type p53. 
The transduced cells, which stably expressed wild-type p53 proliferated at the same 
rate as parental cells. However the sensitivity to radiation was significantly improved 
and the tumour cells became markedly susceptible to chemotherapy compared to the 
parental cells. Therefore forced expression of wild-type p53 gene can increase the 
sensitivity to DNA damage in oesophageal cells [77].
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Loss of bax expression has been reported to be associated with poor response 
to chemoradiotherapy in breast cancer [78]. The situation regarding bcl-2 and bax as 
regards oesophageal cancer is not as clear-cut. There have been several studies, all 
assessing the effect of the two proteins individually. The methodology of these was 
the same. The original biopsy specimens of the tumours, or samples of the surgically 
resected specimen were used for immunohistochemical detection of bcl-2 and bax and 
these were correlated with the known response to chemoradiotherapy. Ikeguchi et al 
used immunohistochemical detection of bax in surgical specimens from the primary 
oesophageal tumours [79]. Bax expression was determined by two independent 
pathologists who had no knowledge of the patients. The percentage of positive tumour 
cells was determined by assessing the whole tumour section. Lymphocytes and 
normal oesophageal epithelium within the sample showed strong bax staining 
intensity and this served as an internal control for bax staining. The specimen was 
decided as bax positive when more than 75% of cancer cells showed unequivocal and 
strong immunoreaction. Bax expression correlated with favourable prognosis in 57 
patients with postoperative chemoradiotherapy [79]
Raouf et al in 2001studied oesophageal tumour resection specimens [80]. 
They were stained for p53 and bcl-2. Sections of human tonsil and colon 
adenocarcinoma known to be positive for bcl-2 and p53 were used as positive 
controls. Out of 2000 tumour cells the number showing moderate to intense 
immunostaining was counted, and the percentage positivity recorded. They found bcl- 
2 (apoptosis inhibitor) expression was not associated with tumour response or 
resistance to chemoradiotherapy [80]. In a further study Sarbia et al stained 
presurgical resection tumour biopsies for p-53, bcl-2, and bax. Using light microscopy 
the immunohistochemical expression was examined by one observer without
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knowledge of the clinical outcome. The percentage of positive tumour cells was 
determined by assessing the whole tumour section. Each sample was assigned to one 
of the following categories. 0 (0-4%), 1 (5-24%), 2 (25-49%), 3 (50-74%), and 4 (75- 
100%). Additionally the intensity of immunostaining was determined as negative, 
weak, and strong. They found no correlation between the expression of bcl-2, bax and 
the response to chemotherapy [81].
The ratio of bcl-2 to bax appears to be more promising in predicting the 
effectiveness of radiotherapy. In a study of prostate cancer immunohistochemical 
analysis of prostate sections for bcl-2 and bax was carried out [82]. Cell counts were 
performed manually using a 10 x 10 microscope grid at x 400 magnification. Both the 
number of immunoreactive cells and the total number of cells were determined by 
visual inspection of four different fields per section. The percent immunoreactivity for 
bcl-2 and bax proteins was based on the ratio of positive cells to the total number of 
cells counted. All counting was performed by two different individuals unaware of 
patient outcome. An elevated bcl-2/bax ratio predicted an increased risk of the cancer 
failing to respond to radiotherapy and indicated that the ratio could be used clinically 
to predict the radioresistance of prostatic tumours [82]. In a study of oesophageal 
cancers and radiotherapy, again using biopsy specimens, the specimens were 
considered immunopositive when >10% of tumour cells had definite immunostaining 
[83]. Ratios of bcl-2 to bax were determined as a quotient of respective 
immunopositive areas. In their study the group responding to radiotherapy had a bcl- 
2/bax ratio favouring bax expression, although the actual values of bcl-2 and bax 
showed no relationship to effectiveness of radiotherapy.
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2.11 SCREENING
An area of dilemma is that of screening for oesophageal cancer. This is 
because there is no consensus as to the best treatment when the diagnosis is made. It 
would seem logical that the only way of improving the survival from oesophageal 
cancer is to detect it early. The Japanese have some of the best survival results in the 
world and they advocate a screening programme of endoscopic examination using 
iodine staining for high-risk groups, such as alcoholics [84], this is obviously not 
practised in the UK, as the incidence of oesophageal cancer here is far lower than that 
in Japan and such a screening programme would not be cost effective. There are also 
ethical considerations in such a programme.
One way of improving the pick-up rate for screening is to target high-risk 
groups such as those with Barrett's oesophagus. It is hoped that this will identify 
cancers at an earlier stage, at which time they may be potentially curable. Indirect 
evidence that surveillance is beneficial comes from observational studies, showing 
that cancers discovered during surveillance are less advanced and associated with 
longer survivals compared those detected during endoscopies performed for 
evaluating cancer symptoms [33].
Even though Barrett's is a strong risk factor for oesophageal adenocarcinoma, 
research has found that survival for patients with Barrett's does not differ significantly 
from that for matched individuals in the general population. For example Eckardt et al 
[85] compared a group of 60 patients with Barrett's oesophagus with 2 other groups 
of patients, the first group was 60 patients with achalasia, and the second was 60 
patients with Schatzki's ring. Achalasia is a condition in which dilatation of the 
oesophagus occurs with retention of solids and liquids [17]. Schatski ring is a 
narrowing of the lower end of the oesophagus due to a ridge of mucosa or a fibrous
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membrane. This may be asymptomatic but can occasionally produce dysphagia [86]. 
The main finding of the study was that overall survival did not significantly differ 
between the three groups. Additionally survival in the patient groups was not 
significantly different from that of the general population. There were 11 deaths in the 
Barrett's group and although 2 subjects in this group developed adenocarcinoma, 
none of the deaths was attributed to cancer.
This may be explained by the low absolute rather than the high relative 
incidence of cancer in Barrett's oesophagus [33]. Studies of survival in patients with 
Barrett's oesophagus have been undertaken predominantly in older men, for whom 
the risk of death from common lethal disorders such as myocardial infarction and 
stroke far exceeds their annual risk of death due to oesophageal carcinoma [33].
In another recent (2001) study of 335 patients with Barrett's 75 died of 
unrelated causes 47 had other diseases limiting survival and 59 were over 75. All 
women, and men with Barrett's <3cm in length were excluded, thus only 52 of the 
original 335 patients (less than 20%) would have benefited from surveillance [87]. 
This has been supported by a further study, in which 59 patients with Barrett's were 
followed. Only two developed oesophageal adenocarcinoma, representing only one 
case in 209 patient years and over 90% of the patients died as a result of unrelated 
causes [88]. In a recent cohort study of Barrett's oesophagus patients among 589 
adenocarcinoma patients only 3.9% had a Barrett's oesophagus diagnosed before their 
cancer [89]. Thus, even if current surveillance techniques are effective, they are 
unlikely to substantially inpact the population's mortality from oesophageal cancer.
There is however some evidence available to suggest that endoscopic 
screening of Barrett's oesophagus is cost effective. Streitz et al [90] undertook a cost 
analysis of endoscopic surveillance to detect adenocarcinoma in Barrett's oesophagus
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compared with mammography used to detect occult carcinoma of the breast. The cost 
of detecting a case of adenocarcinoma in Barrett's oesophagus was $37,928 and of 
detecting a case of breast cancer was $54,513. Endoscopic surveillance of patients 
with Barrett's oesophagus compared favourably with surveillance mammography and 
should be considered to be as cost effective.
Evidence is also available to show that screening of patients with Barrett's 
oesophagus should extend life. Provencale et al [91] recommend five yearly 
endoscopic screening. This cost $98,000 per quality adjusted life year (QALY) 
gained, as compared with heart transplantation ($160,000 per QALY gained) and 
screening for tuberculosis ($216,000 per QALY gained). No matter what the evidence 
is for or against, some practitioners prefer to perform surveillance rather than miss 
curable neoplasms [33].
Surveillance-detected Barrett's oesophagus associated adenocarcinomas are 
accompanied by low-stage disease and improved survival according to the findings 
published by Corley et al [89]. This was a cohort study of 23 Barrett's oesophagus 
patients, among 589 oesophageal or gastric cardia adenocarcinoma patients diagnosed 
between 1990-1998. Among these 23 patients 73% of the surveillance-detected cancer 
patients were alive at the end of follow up, compared with none of the patients 
without surveillance-detected cancers (p=0.001). All surveillance-detected cancer 
patients had low-stage disease and none died directly from cancer.
These findings are supported by van Sandick et al [92]. A clinicopathological 
comparison was made between patients who initially presented with oesophageal 
adenocarcinoma (n=54) and in those in whom the cancer had been detected during 
surveillance of Barrett's oesophagus (n=16). Surgical pathology showed that surveyed 
patients had significantly earlier stages than non-surveyed patients (p=0.0001). Only
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one surveyed patient (6%) versus 34 non-surveyed patients (63%) had nodal 
involvement (p=0.0001). Two-year survival was 85.9% for surveyed patients and 
43.3% for non surveyed patients (p=0.0029).
2.12 ANTIOXIDANTS
Reactive oxygen species (oxidants) are products of partial reduction of 
molecular oxygen. They are formed in the body as a result of regular metabolic 
transformations. An important source of reactive oxygen species is transformations 
associated with cytochrome p 450. This cytochrome metabolises a number of various 
substances, including drugs, and aromatic hydrocarbons present in smog and tobacco 
smoke. Another important source of reactive oxygen species is the oxidative stress 
resulting from inflammatory processes, which is associated with the metabolism of 
every organism [93].
Malignancies fall within the category of diseases whose pathogenesis is 
postulated to be related to the reactive oxygen species effects. Their intensified 
production, deficiency of antioxidants or impairment of the repair mechanism result in 
the increase in processes responsible for the development of malignancies [94].
To counter the effect of oxidising agents, collectively referred to as oxidants, 
cells have antioxidant systems. These include enzymes that break down oxidants and 
molecules that react with free radicals. Antioxidants are naturally occurring trace 
elements, collectively referred to as micronutrients. These include substances as 
varied as zinc, selenium and copper. Vitamins such as vitamins A, C and E are also 
antioxidants. These can all be found in various food substances in the diet.
Micronutrient deficiency can mimic radiation (or chemicals) in damaging 
DNA by causing single and double strand breaks or both. Double strand breaks are a
28
strong predictive factor for human cancer. Those micronutrients whose deficiency 
mimics radiation include Vitamin C, E and Zinc [94].
2.13 SELENIUM
Selenium is a trace element that is essential in small amounts, but can be toxic 
in larger amounts [95]. The main dietary sources of selenium are brazil nuts and 
grains. It is also found in fish, meat and bread. The recommended dietary allowance 
of selenium is 55mcg a day [96]. Humans and animals require selenium for the 
function of a number of selenium-dependent enzymes, also known as selenoproteins 
[97].
Thioredoxin reductase is such a selenoprotein. In conjunction with the 
compound thioredoxin, thioredoxin reductase participates in the regeneration of 
several antioxidant systems, possibly including vitamin C [98]. Selenium is also a 
component of gluathione peroxidase. Four selenium-containing glutathione 
peroxidases (GPx) have been identified: cellular or classical GPx, plasma or 
extracellular GPx, phospholipid hydroperoxide GPx and gastrointestinal GPx. 
Although each GPx is a distinct selenoprotein, they are all antioxidant enzymes that 
reduce potentially damaging reactive oxygen species, such as hydrogen peroxide and 
lipid hydroperoxides, to harmless products like water and alcohols by coupling their 









Figure One. Function of Selenium and Glutathione Peroxidase in the reduction of
free radicals. [100]
Thyroid hormone deiodinases are selenium dependent. The thyroid gland 
releases very small amounts of biologically active thyroid hormone (triiodothyronine 
or T3) and larger amounts of an inactive form of thyroid hormone (thyroxine or T4) 
into the circulation. The conversion of the inactive form to the active form is 
catalysed by thyroid hormone deiodinases. This makes selenium an essential element 
for normal development, growth and metabolism through the regulation of thyroid 
hormones [99].
As an integral part of the glutathione peroxidases and thioredoxin reductase, 
selenium probably interacts with every nutrient that affects the prooxidant/antioxidant 
balance of the cell. Other minerals that are critical components of antioxidant 
enzymes include copper and zinc. Selenium as gluthathione peroxidase also appears 
to support the activity of vitamin E in limiting the oxidation of lipids [95].
Insufficient selenium intake results in decreased activity of the glutathione 
peroxidases. Even when severe, isolated selenium deficiency does not usually result
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in an obvious clinical illness. However, selenium deficient individuals appear to be 
more susceptible to additional physiological stresses [95]. Clinical selenium 
deficiency has been identified in chronically ill patients who were receiving total 
parenteral nutrition (TPN) without added selenium for prolonged periods of time. 
Muscular weakness, muscle wasting and cardiomyopathy (inflammation and damage 
to the heart muscle) have been observed in these patients. TPN solutions are now 
supplemented with selenium to prevent such problems [95]. People who have had a 
large portion of the small intestine surgically removed or those with severe 
gastrointestinal problems, such as Crohn's disease, are also at risk for selenium 
deficiency due to impaired absorption [95].
2.14 ZINC
Zinc is an essential trace element for all forms of life. The main dietary 
sources of zinc are shellfish, beef and other red meats. It is also found in nuts and 
legumes (peas and beans). The recommended dietary allowance of zinc is 11 mg/day 
[100]. Numerous aspects of cellular metabolism are zinc-dependent. Zinc therefore 
plays important roles in growth and development, the immune response, neurological 
function and reproduction [101].
Nearly 100 different enzymes depend on zinc for their ability to catalyze vital 
chemical reactions. Zinc plays an important role in the structure of proteins and cell 
membranes [102]. Loss of zinc from biological membranes increases their 
susceptibility to oxidative damage and impairs their function [103]. Zinc proteins 
have been found to regulate gene expression [104].
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2.15 COPPER
Copper is an essential trace element for humans and animals. It is found in a 
wide variety of foods and is most plentiful in meats, shellfish, nuts and seeds. The 
recommended dietary allowance is 900mcg [105]. Copper can easily accept and 
donate electrons and this explains its important role in oxidation-reduction reactions 
and the scavenging of free radicals [105].
Copper is a critical functional component of a number of essential enzymes, 
known as cuproenzymes. The copper-dependent enzyme, cytochrome c oxidase plays 
a critical role in cellular energy production [106]. Another cuproenzyme, lysyl 
oxidase is required for the cross-linking of collagen and elastin, which are essential 
for the formation of strong and flexible connective tissue [107].
A number of reactions essential to normal function of the brain and nervous 
system are catalyzed by cuproenzymes, eg neurotransmitter synthesis, metabolism of 
neurotransmitters, formation and maintenance of myelin and also melanin formation 
in the skin [100]. Clinically evident or frank copper deficiency is very uncommon and 
occurs under unusual conditions such as patients receiving total parenteral nutrition 
[107].
2.16 VITAMIN E
The term vitamin E describes a family of eight antioxidants; four tocopherols, 
alpha (a), beta (P), gamma (y) and delta (5) and four tocotrienols (also a, P, y, and 5). 
a-Tocopherol is the only form of vitamin E that is actively maintained in the human 
body and is therefore the form of vitamin E found in the largest quantities in the blood 
and tissue [108]. Because a-tocopherol is the form of vitamin E that appears to have
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the greatest nutritional significance, it will be the primary topic of the following 
discussion. Major sources of a-tocopherol in the diet include vegetable oils (olive, 
sunflower, safflower oils), nuts, whole grains and green leafy vegetables. The 
recommended dietary allowance isl5mg/day [100].
The main function of a-tocopherol in humans appears to be as an antioxidant. 
Fats, which are an integral part of all cell membranes, are vulnerable to destruction 
through oxidation by free radicals. The fat-soluble vitamin, a-tocopherol, is uniquely 
suited to intercepting free radicals and preventing a chain reaction of lipid 
destruction. Aside from maintaining the integrity of cell membranes throughout the 
body, a-tocopherol also protects the fats in low density lipoproteins (LDLs) from 
oxidation. Oxidized LDLs have been implicated in the development of cardiovascular 
diseases. When a molecule of a-tocopherol neutralizes a free radical, it is altered in 
such a way that its antioxidant capacity is lost. However, other antioxidants, such as 
vitamin C, are capable of regenerating the antioxidant capacity of a-tocopherol [109].
Vitamin E deficiency has been observed in individuals with severe 
malnutrition, genetic defects affecting the a-tocopherol transfer protein and fat 
malabsorption syndromes [110]. Severe vitamin E deficiency results mainly in 
neurological symptoms such as impaired balance and coordination and muscle 
weakness. The developing nervous system appears to be especially vulnerable to 
vitamin E deficiency as seen in children with severe vitamin E deficiency from birth, 
who are not treated with vitamin E and who develop neurological symptoms rapidly 
[110]. In contrast, individuals who develop malabsorption of vitamin E in adulthood 
may not develop neurological symptoms for 10-20 years. Interestingly however
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symptomatic vitamin E deficiency in healthy individuals who consume diets low in 
vitamin E has never been reported [110].
2.17 VITAMIN C
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin, which is 
essential for normal functioning of the body. Unlike most mammals, humans do not 
have the ability to make their own vitamin C. We must therefore obtain vitamin C 
through our diet. The main sources of Vitamin C are citrus fruits and fresh vegetables. 
The recommended dietary allowance is 90mg/day [100].
Vitamin C is required for the synthesis of collagen, an important structural 
component of blood vessels, tendons, ligaments and bone [111]. Recent research also 
suggests that vitamin C is involved in the metabolism of cholesterol to bile acids, 
which may have implications for blood cholesterol levels and the incidence of 
gallstones [112].
Vitamin C is also a highly effective antioxidant. Even in small amounts 
vitamin C can protect essential molecules in the body, such as proteins, lipids, 
carbohydrates and nucleic acids (DNA and RNA) from damage by free radicals and 
reactive oxygen species. Vitamin C may also be involved in the regeneration of other 
antioxidants such as vitamin E [111].
Severe vitamin C deficiency has been known for many centuries as the 
potentially fatal disease, scurvy. Symptoms of scurvy include bleeding and bruising 
easily, hair and tooth loss, joint pain and swelling. Such symptoms appear to be 




Vitamin A is a generic term for a large number of related compounds. Retinol 
and retinal are often referred to as preformed vitamin A [113]. The main dietary 
sources of Vitamin A are Cod liver oil and dairy products. The recommended dietary 
allowance is 900mcg/day. Inadequate retinol available to the retina results in impaired 
dark adaptation, known as "night blindness" [114].
Vitamin A is commonly known as the 'anti-infective vitamin' because it is required 
for normal functioning of the immune system [115]. Vitamin A deficiency can thus be 
considered a nutritionally acquired immunodeficiency disease [116].
2.19 NEOPLASTIC PROGRESSION
Neoplastic progression in Barrett's oesophagus shows a multistep progression 
from normal squamous mucosa to Barrett's metaplasia, to indefinite or low-grade 
dysplasia, to high-grade dysplasia and finally to invasive carcinoma [117]. If there are 
high levels of cellular proliferation in Barrett's oesophagus this is associated with a 
high risk of progression to adenocarcinoma [118-120].
2.20 THE CELL CYCLE
Every dividing cell passes through a cell cycle. This is an ordered set of 
events, culminating in cell growth and division into two daughter cells. Non-dividing 
cells are not considered to be in the cell cycle. The stages shown in figure two on page 
36 are Gl, S, G2, M. Gl stands for GAP 1. This is for growth and preparation of 
chromosomes for replication. The S stage stands for Synthesis. This is the stage when 
DNA replication occurs. The G2 stage stands for GAP 2. This is preparation for
35
mitosis. M stands for mitosis when nuclear and cytoplasmic division occurs [121]. 
(Fig 2). Abnormal accumulation of cells in the S phase (>7%) and in the G2 phase 










Figure Two. The cell cycle. [121]
2.21 ANTIOXIDANTS IN BARRETT'S
A recent study (2000) measured the cell proliferation in biopsies of Barrett's 
tissue [123]. hi this study elevated proportions in the S and G2 phases predict 
progression to adenocarcinoma. The percentage of cells in the G2 phase is negatively 
associated with dietary selenium. Selenium from breads and grains is negatively 
associated with the percentage of cells in the S phase and in the G2 phase. This 
suggests that decreasing dietary selenium intake and serum levels may increase the 
risk of progression of Barrett's oesophagus to adenocarcinoma.
In a study from Korea, Lee et al induced reflux oesophagitis, both acute and 
chronic in rats. DA-9601, a drug possessing antioxidative properties was administered 
to the rats. It was found that DA-9601, significantly attenuated the gross and
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histopathologic scores of acute reflux oesophagitis in a dose dependent manner 
compared to those treated with Ranitidine (an acid suppression drug) alone. It was 
also found that D-9601 prevented the development of Barrett's oesophagus in the 
chronic reflux oesophagitis model (p<0.05) [124].
Rudolph et al [125] evaluated serum selenium levels in patients with Barrett's 
oesophagus enrolled in a surveillance programme. The authors found that low 
selenium levels were associated with an increased risk of progression to high-grade 
dysplasia and loss of wild type p53. It was also found that higher serum selenium 
levels may be associated with a reduced risk of oesophageal adenocarcinoma among 
persons with Barrett's oesophagus.
The most recent study (2004) is published by Fountoulakis et al [15]. Blood 
samples and endoscopic biopsies (squamous, Barrett's, and gastric) were obtained 
from 48 Barrett's patients, while 48 age and sex-matched controls provided blood 
samples only. Plasma concentrations of Vitamins A, C, and E were measured in all 
subjects, while Vitamin C was measured in relation to the type of mucosa. Plasma 
total Vitamin C level was lower in Barrett's patients compared to controls (p=0.014). 
Tissue levels of total Vitamin C were significantly lower in Barrett's compared with 
squamous mucosa (p=0.047). The authors concluded the lower levels of Vitamin C in 
plasma of Barrett's patients and in Barrett's mucosa compared with squamous mucosa 
are consistent with oxidative stress being of importance in the pathogenesis and 
neoplastic progression of Barrett's esophagus. There is a paucity of information in the 
literature relating to antioxidants and Barrett's oesophagus, and a literature search has 
not found any published study to challenge the above evidence.
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2.22 NUTRITION AND CANCER
There have been many studies looking at the risk factors for developing 
cancer of the oesophagus and a large number of these have looked at the role of diet. 
The first indication that nutritional deficiencies may affect oesophageal cancer risk 
was provided by the association of the disease with Plummer-Vinson or Patterson- 
Kelly syndrome [126]. This syndrome is characterised by hypochromic anaemia and 
changes in the hypopharynx and upper oesophagus, which are associated with 
dysphagia and the development of cancer. Originally thought to be only the result of 
iron deficiency, other nutritional deficiencies may be important as well.
A review article from the Department of Epidemiology and Public Health in 
Yale Medical School analysed dietary factors and their role in the aetiology of 
adenocarcinomas of the oesophagus, and gastric cardia [127]. Diets high in total fat, 
saturated fat and cholesterol were associated with an increased risk of developing 
these cancers. The influence of the Mediterranean diet on the risk of cancers of the 
upper aerodigestive tract was assessed by Bosetti et al [128]. The cases included 598 
cases of cancer of the oral cavity and pharynx, 304 cases with oesophageal squamous 
cell carcinoma, and 460 laryngeal cancer cases. A score summarising eight of the 
major characteristics of the Mediterranean diet was used. For all cancers considered, a 
reduced risk was found for increasing levels of the Mediterranean diet score, 
providing evidence that a defined nutritional pattern, which includes several aspects 
of the Mediterranean diet, favourably affects the risk of cancers of the upper 
aerodigestive tract. Galeone et al [129] investigated the role of fried foods on oral 
pharyngeal, and oesophageal cancers, and found that consumption of fried foods 
increased the risk of both cancer types. Finally Gonzalez et al [130], as part of the 
European Prospective Investigation into Cancer and Nutrition, investigated the risks
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of gastric cancer and oesophageal adenocarcinoma associated with meat consumption. 
Oesophageal cancer was not affected, but gastric non-cardia cancer was associated 
with intakes of total meat, especially red meat.
2.23 ANTIOXIDANTS AND SQUAMOUS CELL CANCER
Of the studies looking at the risk factors for oesophageal cancer a very small 
number have mentioned antioxidants and in particular Selenium. The majority of 
papers available focus mainly on adenocarcinoma, and there are a few which discuss 
the role of antioxidants in the diet and the development of squamous cell carcinoma. 
In the next section papers relating to squamous cell carcinoma and adenocarcinoma 
will be discussed. Due to the large numbers of papers available on the subject a 
selection relevant to the discussion will be considered.
There is now sufficient literature to support the view that a diet rich in 
antioxidants will lead to a lower incidence of squamous cell cancer of the oesophagus. 
The first relevant paper was from the USA in!998 and assessed the dietary factors in 
patients with squamous cell carcinoma [3]. The findings were significant, in that 
protective effects were found with increased consumption of raw fruits and vegetables 
and the use of vitamin supplements, especially Vitamin C. Elevated risks of 
oesophageal cancer were associated with high versus low intake of red meat [3].
A French study compared the incidence of squamous cell cancer with diet in 
three different regions, each with different diet and drinking habits, [4] after 
adjustment for drinking and smoking, it was apparent that low consumption of fresh 
fish, vegetables and fruits and a high consumption of butter were associated strongly 
and independently with an increase in oesophageal cancer risk. Vitamins D, E, and
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phosphorus were protective factors, whilst cholesterol appeared as a risk factor in 
cancer development [4].
In a study based in Shanghai, China, with 902 cases and 1,552 controls (after 
adjustment for cigarette smoking, alcohol consumption and other risk factors for 
squamous cell cancer) the authors found that increasing consumption of fruit, dark 
orange vegetables and beef/mutton was associated with statistically significant 
decreased trends for oesophageal cancer. In general, risks were about 40% lower 
amongst those in the upper versus lower quartiles of intake of these foods. Nutrient 
analysis revealed that increased dietary intake of protein, carotene, Vitamins C and E 
and riboflavin was associated with a reduced oesophageal cancer risk [5].
In a review article on the relationship between nutrition and oesophageal 
cancer seventy-six separate studies were reviewed. Most pertained to squamous rather 
than adenocarcinoma. It was found that the protective effect of fruit and vegetable 
consumption was supported by a large body of evidence, especially from case control 
studies [6]. Furthermore in a study carried out in South Carolina significantly 
increased risks of oesophageal cancer were associated with low intake of fruits, 
particularly citrus fruits and juices [7].
Other studies have not only shown that antioxidant intake is associated with 
risk reductions for oesophageal cancer, but also that the protective effect is stronger in 
patients who indulge in other risk factors for squamous cell carcinoma namely 
smoking and alcohol. A Swedish paper observed that the higher the intake of Vitamin 
C, Alpha-tocopherol and Beta-carotene the lower the risk of oesophageal cancer. This 
effect was most marked with beta-carotene, showing an inverse association with both 
histological types of oesophageal cancer, with risk reductions of 40-50% in the 
highest quartile versus the lowest. The inverse associations of antioxidants with
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squamous cell carcinoma also appeared stronger amongst current smokers than 
amongst patients who have never smoked [8]. This would suggest that the inverse 
associations are stronger amongst subjects under higher oxidative stress and that 
protection is conferred through an anti-oxidative mechanism [8]. This has been further 
supported by a Greek study showing that the high levels of consumption of fruit and 
vegetables in their diet attenuated the harmful effects of smoking on the oesophagus 
[9]-
The protective effect of antioxidants is also extended to alcohol. In a Greek 
population study it has been postulated that the high levels of alcohol drunk in the 
form of wine with meals is protected against by the high levels of fruit and vegetables 
taken with the alcohol, thus reducing the impact of ethanol on the oesophageal 
mucosa [9]. Support for these two speculative explanations is provided by the 
relatively low ratio values linking specified tobacco and ethanol increments to 
oesophageal cancer risk in their data [9],
2.24 ANTIOXIDANTS AND ADENOCARCINOMA
The results pertaining to adenocarcinoma are very much the same as for squamous 
cancer. There is a general agreement in the literature that the higher the intake of 
antioxidants in the form of fresh fruit, vegetables and supplements, the lower the risk 
of developing adenocarcinoma of the oesophagus.
A recent publication (2000) in the British Journal of Cancer looked at the role 
of diet and other socioeconomic factors, amongst women. A dietary questionnaire was 
used to obtain information for recent diet (3 years prior to interview) and at the age of 
30 years. Consumption of fresh fruit, salad and vegetables was assessed by questions 
on food frequency. It was found that a high consumption of fruit was protective, as
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was frequent use of salad vegetables. However these findings were not statistically 
significant, which the authors felt to be due to a limited sample size (74 cases) [10].
A much larger study of 483 patients, which looked only at the role of diet 
found that there was a statistically significant decreased risk of oesophageal 
adenocarcinoma associated with high intakes of poultry and fish, fruits including 
apples or pears, apricots, bananas, fresh peaches or nectarines, canned peaches, 
watermelon and citrus [11].
In 1996 the population of Greece had a mortality from oesophageal carcinoma 
of only 3.57100 000 and is therefore a very low risk population. The role of diet was 
assessed, again by means of a food questionnaire, reporting the average frequency of 
consumption of 115 food or beverage items for the period of one year for each patient 
prior to the onset of their disease. The Greeks have a very specific diet and it was the 
purpose of this study to assess if their diet had a protective effect with respect to 
oesophageal malignancy. It was observed that added oils and fats-perhaps 
polyunsaturated fats were positively associated with adenocarcinoma, whereas 
vegetables, Vitamin A, Beta- Carotene, Vitamin C and fruits were negatively 
associated. Furthermore one of the findings in this particular study was that these 
associations were stronger for adenocarcinoma than for squamous cell carcinoma 
[12].
Another study performed in the United States, again confirmed decreased risks 
for oesophageal cancer being seen for consumption of fruits and vegetables, 
especially cruciferous vegetables such as broccoli. For consumers of raw fruits, raw 
vegetables and cruciferous vegetables, the risks for oesophageal adenocarcinoma for 
the highest intake levels were significantly reduced when compared with those for the 
lowest categories [13].
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A 1997 paper by Gammon et al [131], which specifically focussed on tobacco, 
alcohol and socio-economic status, with respect to oesophageal adenocarcinoma 
found that although the incidence of adenocarcinoma was not affected by alcohol 
drinking in general there was a 40% decrease associated with wine drinking. It was 
postulated that there may be a protective ingredient in wine. It was also suggested that 
this trend may have been a result of sampling bias, as the consumption of wine in 
their population-based control subjects was higher and also higher amongst those who 
were male, white and younger in age and who reported a higher income, education 
and intake of beer and liquor.
2.25 SELENIUM AND CANCER RISK
Selenium has been proven to reduce cancer risk for many different types of 
cancer. The blood serum selenium levels have been measured in healthy subjects in 
six districts in the province of Merida, Venezuela [132]. There were either high or low 
serum-selenium containing districts. On the average a reduction of cancer incidence 
was observed in the districts with high serum selenium contents and in all cases 
evaluated, lower serum selenium values were observed in lung, stomach, hepatic, 
miscellaneous and total cancer patients as compared with the mean value for healthy 
individuals.
Furthermore, some of the most recent publications relate to the Nutritional 
Prevention of Cancer Trial. This was a randomised clinical trial designed to evaluate 
the efficacy of selenium as selenized yeast (200mcg daily) in preventing the 
recurrence of non-melanoma skin cancer among 1312 residents of the Eastern United 
States. Patients with histories of basal/squamous-cell carcinoma of the skin were 
assigned randomly in double-blind fashion to daily oral supplements of either
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selenium, or a low selenium placebo. The primary end-points were the incidences of 
basal cell or squamous cell carcinomas of the skin. Secondary end-points were all- 
cause mortality, total cancer mortality, total cancer incidence and the incidences of 
lung, prostate and colorectal cancers. Selenium treatment did not significantly affect 
the incidence of basal or squamous cell carcinoma of the skin. There were 377 new 
cases of basal cell carcinoma in the selenium group and 350 cases in the control 
group. There were significant reductions in total cancer mortality (29 deaths in the 
selenium group and 57 deaths in controls) and total cancer incidence (77 cancers in 
the selenium group and 119 in controls) [133]. Original secondary analyses showed 
striking inverse associations between treatment and the incidence of total cancer 
numbers, lung, prostate and colorectal cancer and total cancer mortality. The 
protective effect of selenium was noted to be confined to males and was most 
pronounced in former smokers. The protective effect was also restricted to those 
patients with lower baseline plasma selenium concentrations [134]. An update was 
published in 2002, with a further 3 years follow-up of the 1312 participants in the 
nutritional prevention of cancer trial. The authors found that selenium 
supplementation did not significantly decrease lung cancer incidence in the 
population, but did significantly decrease the incidence amongst individuals with low 
baseline selenium concentrations [135].
A Finnish study looking specifically at the effect of selenium on lung cancer 
found a significant inverse association between serum selenium and subsequent 
cancer occurrence. It was also suggested that there was a stronger inverse association 
between serum selenium and lung cancer risk in the subpopulation of individuals with 
low serum levels of alpha-tocopherol (Vitamin E) [136]. This supports the theory that 
vitamin E reduces the oxidative damage seen in selenium deficiency [137]. This
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finding has been supported by a very similar study, again from Finland, which looked 
at toenail selenium concentration, in male smokers only. Low selenium status was 
associated with an increased risk of lung cancer [138].
Evidence exists for an inverse association between selenium and bladder 
cancer risk. In the Netherlands Cohort study selenium levels were measured in toenail 
clippings in patients suffering with bladder cancer, a subcohort of 3,500 subjects was 
randomly sampled from the main cohort of over 100,000 subjects. Toenail clippings 
were provided by 438 patients with bladder cancer and 2569 controls. It was 
demonstrated that there was a small inverse association between toenail selenium and 
bladder cancer risk (p< 0.01). This was largely limited to the highest three quintiles of 
the toenail selenium distribution. The association was most pronounced in ex-smokers 
(p<0.01) and was independent of beta-carotene, Vitamin C and Vitamin E intake 
[139]. The authors concluded that the evidence is in favour of an inverse association 
between selenium and bladder cancer risk.
Not all data have found an association between serum selenium and the risk of 
cancer. A study looking at toenail selenium levels and bladder cancer risk, observed 
no association between toenail selenium concentrations and cancer risk among male 
smokers. However, there was a major limitation in this study as the toenail selenium 
levels changed over time due to the national agricultural soil fortification that 
occurred during the study period and the possibility that bladder cancer risk may be 
elevated at selenium concentrations lower than those observed in the study could not 
be excluded [140].
In a prospective study of toenail selenium levels and cancer among women no 
inverse association was found between selenium levels in toenails and cancer risk 
[141]. It was also noted that cancer and its treatment lowers the levels of selenium
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and that levels are lower in current smokers, both factors should therefore be 
considered when reviewing the evidence above.
Selenium has also been found to lower the risk for colorectal adenomas [142]. 
It has been demonstrated that individuals with high plasma selenium levels are at 
decreased risk for colorectal adenomas. In this study an increase of 30 micrograms per 
litre in plasma selenium was associated with approximately 50% risk reduction of 
adenomatous polyps, even after adjustment for potential confounding variables, such 
as fat, fibre and antioxidant vitamins. In addition those individuals in the highest 
quartile of plasma selenium level were at much lower risk of colorectal adenomas 
than those in the lowest quartile.
In a multicentre study from the United States selenium deficiency has been 
implicated in the aetiology of prostate cancer, hi this population-based, case-control 
study it was found that serum selenium was inversely associated with the risk of 
prostate cancer. Consistent with other studies, the inverse association was strongest 
among men with low serum alpha-tocopherol (Vit E) concentrations [143].
Another interesting and relevant study has been published from China 
measuring the effect of nutritional intervention in a region with epidemic rates of 
squamous oesophageal and adenomatous gastric cardia cancers [14]. Serum selenium 
levels were measured pre-trial and subjects were given selenium, beta-carotene and 
Vitamin E supplements. Selenium levels were then measured in 590 case subjects 
with oesophageal cancer, 402 with gastric cardia cancers and 87 with gastric non- 
cardia cancers as well as in 1062 control subjects. It was found that there were highly 
significant inverse associations of serum selenium levels with the incidence of 
oesophageal and gastric cardia cancers. Participants receiving supplements had a 42% 
reduction in oesophageal cancer prevalence. Conversely, the population proportion of
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these cancers that was attributable to low selenium levels was 26.4%. Lastly there was 
no evidence for a gradient of serum selenium associated with the incidence of gastric 
non-cardia cancer.
In India, reverse smoking of chutta-rolled tobacco leaf is common practice. A 
chutta is a cheroot made from rolled tobacco leaves, this is then smoked by placing 
the lit end of the chutta in the mouth. This practise is a well-known risk factor for 
cancers of the upper aerodigestive tract. A study published in 2000 looked at the 
impact of Vitamin A, riboflavin, zinc and selenium in subjects with and without 
precancerous lesions in these high risk smokers [144]. 150 subjects received 
micronutrients and 148 controls received a placebo. Clinically complete remission of 
white, red and combination pre-cancerous lesions was seen in 57% of subjects on 
supplements whereas only 8% on placebo showed any positive response. One of the 
major limitations of this study was that it was not possible to attribute cancer 
remission to any individual micronutrient.
2.26 THE ROLE OF SUPPLEMENTATION
It would seem from the above publications that there is some evidence to 
support the view that selenium may have an anticarcinogenic effect. Furthermore, 
epidemiologic studies show that cancer incidence is higher in areas where soil 
selenium is low [145]. If this is the case then the question arises as to whether there is 
a role for selenium as a prophylactic drug in cancer.
The double-blind, placebo-controlled, randomised cancer prevention trial 
published using a nutritional dose of Selenium has previously been discussed [133]. 
The magnitude of the apparent effects on cancer incidence and cancer mortality was 
unexpected, in fact the blinded phase of the trial was stopped early due to this.
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During the trial there were no reported side effects of selenium, although it is possible 
to suffer side effects if selenium is taken in high doses [146].
Selenium has both anti-mutagenic and mutagenic properties depending on the 
concentration and chemical form. At physiological levels found in blood, selenium 
has an anti-mutagenic property, but at greater concentrations mutagenicity has been 
observed [146]. It is not known if large amounts of selenium consumption can cause 
cancer in humans. A critical review of the afore mentioned study suggested that the 
lack of an effect on the primary endpoint (skin cancer) and the significant protection 
from the secondary endpoints is confusing. The authors suggest that similarly 
designed studies should be repeated with lung, prostate and colorectal cancer as the 
primary endpoints. It has been suggested that normalisation of selenium status 
through selenium repletion can protect high-risk groups from cancer. [147].
2.27 ANTIOXIDANTS AND CANCER RISK
The evidence for the cancer preventing properties of other antioxidants is not 
as clear-cut as that for selenium. The major body of evidence for selenium points 
towards there being anti-cancer properties. The data with reference to other 
antioxidants are equivocal. The evidence available supporting the anti-cancer 
properties of antioxidants excluding selenium has also been considered.
A paper from Texas looked at the role of isotretinoin (Vit A) in the prevention 
of both recurrent and secondary head and neck cancers. Patients who were disease 
free after primary treatment of squamous-cell cancers were randomly allocated to 
receive either isotretinoin or placebo taken daily for twelve months. There were no 
significant differences between the two groups in the number of recurrences, but the 
isotretinoin group had significantly fewer second primary rumours [148].
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There have been several studies, which have assessed the role of antioxidants 
and the development of lung cancer. An early study from the USA involved 
supplementing the diet of 73 men with a history of 20 or more pack-years of cigarette 
smoking with either placebo, or folate and Vitamin B12. All the subjects were known 
to have bronchial squamous metaplasia. Direct cytological comparison of the two 
groups after four months showed significantly greater reduction of atypia in the 
supplemented group. This was evidence that atypical bronchial squamous metaplasia 
maybe reduced by supplementation with folate and Vitamin B12. The authors did 
admit that significance of the findings was tempered by substantial spontaneous 
variation in sputum cytologies, the small study population and the short duration of 
the trial [149].
An Italian study explored the possibility of using Vitamin A as a form of 
treatment for patients with non-small-cell lung cancer. Following 'curative' surgery, 
patients were randomly assigned to either a group prescribed retinol palmitate or a 
control group prescribed no treatment. Following 46 months the number of patients 
with either recurrence or new primary tumour was 37% in the treated arm and 48% in 
the control arm. A statistically significant difference (p=0.045) in favour of treatment 
was therefore observed [150].
A nested case-control study was conducted within the Alpha-Tocopherol, 
Beta- Carotene Cancer Prevention study cohort to test for associations between 
selected B-Vitamins (folate, Vitamin B6, Vitamin B12) and the incidence of lung 
cancer. Compared with men with the lowest Vitamin B6 concentration, men in the 
fifth quintile had approx one half of the risk of lung cancer. Adjusting for any of the 
other serum factors (folate, B12) either alone or jointly did not significantly alter these 
estimates [151].
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There is also some evidence in favour of a role of micronutrient deficiency in 
the development of adenomatous polyps of the large bowel and the subsequent 
development of colorectal cancer. A Canadian double-blind randomised trial was 
designed to examine the effects of Vitamins C and E on the rate of recurrence of 
colorectal polyps. 200 patients free of polyps after removal of at least one were 
randomised to receive a supplement of Vitamin C and E or a placebo. A second 
colonoscopy was planned after two years of supplementation. Polyps were observed 
in the second colonoscopy in 41% of 70 subjects on supplementation and in 51% of 
67 subjects on placebo. The findings of the investigation suggested that any reduction 
in the rate of polyp recurrence associated with vitamin supplementation was small and 
a larger study would be required to ensure that an effect of this size was not a purely 
chance finding [152].
A similarly designed study from Italy evaluated 209 patients. The study group 
was given Vitamins A, C and E and these were compared with a control group. 
Polyps recurred in 6% of the individuals given vitamins and 36% of untreated 
controls (p<0.001). This study suggested therefore that antioxidant vitamins could be 
effective in reducing the recurrence rate of adenomatous polyps [153].
Antioxidants have also been shown to have an effect on gastric and 
oesophageal cancer. The previously discussed nutrition intervention trial carried out 
in Linxian, China, also looked at other antioxidants. Subjects were given four 
combinations of nutrients. A. retinol and zinc. B. riboflavin and niacin. C. vit C and 
molybdenum and D. beta-carotene, vit E and selenium. The selenium results have 
been discussed above. It was found that the prevalence of gastric cancer among 
participants receiving retinol and zinc was 62% lower than those not receiving those 
supplements (p=0.09) [154].
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In the previous selenium section the bulk of evidence available supported its 
anti-cancer properties. This is clearly not the case for other antioxidants, because there 
is a large number of studies, which have failed to demonstrate any convincing 
evidence of anti-cancer properties.
The first of these is a large randomised, double-blind, placebo-controlled trial 
of beta-carotene, in which 22,071 male subjects were enrolled. Among 11,036 
randomly assigned to receive beta-carotene and 11,035 randomly assigned to receive 
placebo, there were virtually no early or late differences in the overall incidence of 
any malignant neoplasm (except non-melanoma skin cancer) or in overall mortality 
[155].
Patients previously treated and 'cured' from head and neck cancers remain at 
high risk for developing a second primary in the head and neck area. Such patients 
were randomly assigned to receive either etretinate, a second-generation retinoid, or a 
placebo for 24 months. Treatment began no later than 15 days after surgery or the 
commencement of radiotherapy. The 5-year survival rate and disease-free survival 
rate were similar in the two groups. It was concluded that etretinate did not prevent 
second primary tumours in patients who have been treated for squamous cell 
carcinoma of the oral cavity and oropharynx [156].
A trial of isotretinoin in lung cancer used as the study group smokers with 
dysplasia/metaplasia on biopsy. These patients were randomly assigned to receive 
either isotretinoin or placebo daily for six months. At the completion of the study it 
was concluded that isotretinoin had no effect on squamous metaplasia [157]. A further 
study investigating the relationship between lung cancer and etretinate carried out in 
Canada included smokers with at least a 15-pack year history. They were screened for 
sputum atypia. Patients were then randomised to receive either etretinate or placebo
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daily. At the end of six months there was no difference in the degree of atypia 
between the two treatment groups [158].
The relationship between antioxidants and lung cancer was disproven by a 
large randomised, double-blind, placebo-controlled trial with a total of 29,133 male 
smokers. They were randomly assigned to one of four regimens: alpha-tocopherol 
alone, beta-carotene alone, both alpha-tocopherol and beta-carotene, or placebo. 
Follow up was continued for five to eight years. This study concluded that there was 
no evidence of an interaction between antioxidants and the development of lung 
cancer [159].
The relationship between lung cancer, beta-carotene and vitamin A was 
investigated in a study of 18, 314 smokers, former smokers and workers exposed to 
asbestos. Subjects were recruited and randomised to receive either beta-carotene and 
vitamin A, or placebo. After an average of four years of supplementation, the 
combination of beta-carotene and vitamin A had no benefit and may even have had an 
adverse effect on the incidence of lung cancer. This randomised trial was therefore 
prematurely stopped due to these findings [160]. Although there is a large volume of 
evidence available regarding antioxidants and lung cancer, research has also been 
conducted to demonstrate the effect of antioxidants on colorectal mucosa.
A randomised controlled trial was conducted in Lebanon, looking at the effect 
of beta-carotene and vitamins C and E on the incidence of colorectal adenoma. 864 
patients were assigned to four treatment groups. Beta-carotene, vitamin C, vitamin E, 
or all three, and a placebo group. Colonoscopies were performed one year and four 
years after recruitment. Neither treatment appeared to be effective in any subgroup of 
patients or in the prevention of any subtype of polyp defined by size or location [161].
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In 1994 as part of the Cancer Prevention Study, analysis was performed to 
look at the effect of multivitamins on colon cancer mortality. It was found that 
multivitamin use showed little association with colon cancer mortality [162]. Another 
study looked at colorectal cancer and vitamin C, E, alpha-or gamma-tocopherol, 
retinal, alpha-or beta-carotene, lycopene, or lutein+zeaxanthin [163]. This was done 
as part of the larger Alpha-tocopherol, Beta-carotene Cancer Prevention Study. Again 
no association was found between baseline serum antioxidant concentrations and 
colorectal cancer. This research also investigated the links with bladder cancer.
A smaller study done as part of the Cancer Prevention Study looked at the 
dietary intakes of alpha-carotene, beta-carotene, lycopene, lutein/zeaxanthin, beta- 
cryptoxanthin, vitamins A, E and C and folate, with respect to the risk of bladder 
cancer. No association was found in reducing the risk of bladder cancer amongst male 
smokers receiving supplementation [164],
In Huixan, China a randomised double-blind intervention trial was carried out 
to determine whether combined treatment with retinol, riboflavin and zinc could 
lower the prevalence of precencerous lesions of the oesophagus. Supplementation 
again did not affect the prevalence of oesophageal lesions: after one year, the 
prevalence of oesophagitis with or without atrophy or dysplasia was 45% in the 
placebo group and 49% in the vitamin/zinc group [165].
A recent study (2002) in the USA looked at the effect of supplementation on 
stomach cancer. The use of individual vitamin C supplements, vitamin E supplements 
and multivitamins among 1 045 923 adults in the Cancer Prevention Study was 
assessed. After adjustment for potential stomach cancer risk factors the results 
suggested that the use of vitamin C, vitamin E, or multivitamins did not substantially
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reduce the risk of stomach cancer mortality rates in these North American populations 
[166].
2.28 SUMMARY
It is widely accepted that there is an increasing incidence of 
oesophageal adenocarcinoma in Western populations [1]. The reasons for this 
increase are not known although it has been postulated to be due to an increase in 
obesity and gastro-oesophageal reflux disease, hence leading to Barrett's [24].
There have been some published studies demonstrating a link between 
squamous cell carcinoma and antioxidant deficiency [3-7]. Four have assessed the 
dietary factors in patients with squamous cell carcinoma as compared to controls, and 
one is a meta-analysis. It was found that a diet rich in antioxidants had an inverse 
association with squamous cell carcinoma of the oesophagus.
The studies discussed pertaining to adenocarcinoma were all conducted in 
much the same way [8-13]. The diet of patients with adenocarcinoma was assessed by 
means of dietary questionnaires and /or interviews. The results were all along the 
same common theme. A diet rich in fresh fruit and vegetables and hence antioxidants 
was inversely associated with adenocarcinoma of the oesophagus.
There have been very few studies on antioxidants and Barrett's. One study 
measured the cell proliferation in biopsies of Barrett's tissue [123]. The findings of 
this study suggested that decreasing dietary selenium intake and serum levels may 
increase the risk of progression of Barrett's oesophagus to adenocarcinoma. More 
recently it was found that patients with Barrett's oesophagus had a lower serum 
Vitamin C level than matched controls, and that Barrett's tissue itself had lower 
Vitamin C levels than normal oesophageal mucosa [15].
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In a study from Korea reflux oesophagitis, both acute and chronic was induced 
in rats. It was found that an antioxidant drug prevented the development of Barrett's 
oesophagus in chronic reflux oesophagitis [124]. In a further study serum selenium 
levels in patients with Barrett's oesophagus enrolled in a surveillance programme 
were measured. It was found that higher serum selenium levels may be associated 
with a reduced risk of oesophageal adenocarcinoma among persons with Barrett's 
oesophagus [125].
Apoptosis is programmed cell suicide, which can be triggered by many 
environmental factors, the most relevant to this discussion being radiation and 
cytotoxic agents [93]. If a cell suffers DNA damage secondary to environmental 
stresses, such as free radicals, or reactive oxygen species, and is not triggered to 
apoptose, that cell then has the potential to develop into a malignancy [93]. In vivo 
studies have shown a protective effect of selenium against apoptosis induced by 
superoxide anions [167]. Apoptosis is regulated by cellular proteins, bcl-2 which 
inhibits, and bax, which promotes. P53 regulates apoptosis indirectly [67]. There 
have been studies discussed which have addressed the possibility that the expression 
of bcl-2, bax, and p53 within a tumour can be used to predict the response of that 
tumour to chemoradiotherapy [75, 77, 82].
At the time this study was undertaken (2003) there was minimal published 
literature studying antioxidant levels in patients with Barrett's oesophagus. There is 
no study to date comparing antioxidant concentrations in patients with Barrett's 
oesophagus, and lesser degrees of oesophageal injury. There have been very few 
studies of the importance of the expression of bcl-2, bax, and p53 in oesophageal 




The incidence of oesophageal adenocarcinoma is increasing [1], possibly due 
to the rise in obesity, and hence gastroesophageal reflux disease [24]. Antioxidants are 
trace elements found in the diet, and they have been shown to protect the cell against 
free radical induced DNA damage, which can potentially lead to carcinogenesis [93]. 
Patients with diets deficient in antioxidants have an increased risk of progression to 
high-grade dysplasia in Barrett's [125] ,and increased risk of developing 
adenocarcinoma [11].
Part of the treatment of oesophageal carcinoma is chemoradiotherapy, which 
is used to trigger tumour cell apoptosis, or cell death. This can be triggered both by 
chemotherapeutics or radiation [67]. Apoptosis is suppressed by bcl-2, and promoted 
by bax [67]. It is theoretically possible to predict a tumours response to 
chemoradiotherapy by measuring the ratio of bcl-2 to bax within the tumour [83]. 
Vitamin C has in vitro been shown to chemosensitise oesophageal cancer cells to 
cisplatin and 5-fluorouracil, exerting a significantly enhanced cytotoxic effect 
compared to both drugs individually [168], antioxidants have been shown to 
participate in the apoptotic pathway of oesophageal carcinoma cells [169].
The aims of the present investigations were to;
A) Investigate the concentrations of certain antioxidants in patients with 
Barrett's oesophagus, and lesser grades of oesophageal injury.
B) To examine whether the expression of the apoptosis-related proteins bcl-2, 
bax and p53 in oesophageal tumour cells can be used to identify the patients who will 
have a good response to chemoradiotherapy.
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2.30 HYPOTHESES
1. That patients with Barrett's oesophagus will have lower serum levels of 
antioxidants (Selenium, Copper, Zinc, Vitamins A, C, E, p-cryptoxanthine, 
and xanthophyll) than control groups.
2. That patients who have a good pathological and clinical response to 
neoadjuvant chemoradiotherapy will have a lower level of the apoptosis 
inhibiting oncogene bcl-2 in the tumour cells, and a bcl-2 to bax ratio 
favouring bax expression.
3. That the patients responding well to neoadjuvant therapy will have a high level 







There are many papers in the literature demonstrating a link between 
oesophageal cancer and serum antioxidant deficiencies [3-14]. Far fewer have 
investigated the link between antioxidant deficiency and the precursor of 
adenocarcinoma, Barrett's oesophagus [15, 123, 125]. In order to investigate whether 
antioxidant deficiency arises as a result of oesophageal carcinoma or the deficiency 
pre-dates the development of carcinoma, this study was set up in order to determine 
the serum antioxidant levels of Vitamins A, C and E, trace elements Selenium, 
Copper and Zinc, and the Carotenoids in patients with histologically confirmed 
Barrett's oesophagus.
3.2 METHODOLOGY
3.2.1 SOURCE OF SERUM SAMPLES
Serum antioxidant profiles were determined for the three prospectively 
identified cohorts of patients outlined below, during the period May-September 2003. 
Full ethical approval was granted by Bro-Taf Local Research Ethics Committee 
(Protocol #03/5011) and the Royal Glamorgan Hospital research and development 
board. Each control subject provided written informed consent for venepuncture and 
was given an information sheet. Appendix I.
1. Patients with Barrett's oesophagus (defined by endoscopic columnar lined 
oesophagus and intestinal metaplasia on biopsy).
2. Patients with erosive oesophagitis on oesophagogastroduodenoscopy 
(OGD).
3. Patient controls with reflux symptoms, but normal endoscopic appearance.
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The cohorts for each study group were identified from all patients attending for 
upper GI endoscopy at the endoscopy suite in the Royal Glamorgan Hospital, 
Llantrisant. All suitable patients were recruited prospectively.
Antioxidants may act as reverse acute phase reactants [170]. This means that 
patients with ongoing ill health or occult inflammatory processes may have reduced 
levels. Patients with ongoing illness or occult inflammation were excluded on the 
basis of either a raised C Reactive Protein (CRP) (>10mg/L) or hypoalbuminaemia 
(<32mg/L). Additional exclusion critera were the presence of gastroduodenal 
ulceration, a history of pancreatitis or prior foregut surgery, other than 
cholecystectomy. In addition any patients with endoscopic Barrett's oesophagus 
whose oesophageal biopsies did not histologically confirm intestinal metaplasia were 
excluded.
For each patient the following information was recorded: age, gender, type, 
and duration of symptoms and the results of the OGD. Results of any histological 
biopsies taken at the time of endoscopy were also recorded. These results were 
collected on a questionnaire proforma. Data were stored on a specifically designed 
database, using a Pentium III personal computer and Microsoft Access with Windows 
2000 home edition.
3.2.2 SAMPLE SIZE DETERMINA TION
For this study we assumed the magnitude of the difference between Barrett's 
and control patients would be of the order of 0.75 standard deviations. Assuming a 




The biochemical parameters assessed comprised plasma concentrations of the 
trace elements selenium, zinc, copper, Vitamin A, C and E. 15mls of blood was 
collected at the time of attendance for OGD. Venous blood was obtained after an 
overnight fast. Samples for trace element analysis were collected in trace element free 
sodium heparin vacutainers (Becton Dickinson, Cedex, France); those for vitamin 
analysis were taken into lithium heparin vacutainers (Becton Dickinson, Cedex, 
France) and transported to the laboratory in a light excluding container. All samples 
were centrifuged within 30 minutes of collection. Separated plasma was divided into 
aliquots and stored at the following temperatures before analysis: trace elements 
minus 20°C, vitamins A and E minus 20°C and vitamin C minus 70°C. Samples were 
stored at this temperature because vitamin C is more thermally unstable than vitamins 
A and E.
The samples were processed in the Department of Biochemistry, University 
Hospital of Wales. Zinc was measured using flame atomic absorption on an AA-10 
spectrophotometer (Varian, Inc., NJ). Selenium was measured by electrothermal 
graphite furnace atomic absorption using a palladium nitrate matrix modifier on an 
AA-600 spectrophotometer (Varian, Inc., NJ). Vitamins A, C and E were ascertained 
by high performance liquid chromatography with spectrophotometric detection using 
wavelengths vitamin A: 327nm; vitamin E:292nm; vitamin C 451nm respectively. 
CRP and Albumin levels were ascertained the biochemistry laboratory, in the Royal 
Glamorgan Hospital. Both were measured by dry slide technology on a Vitros 950 
analyser (Ortho-Clinical Diagnostics, Amersham, Bucks, U.K.).
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3.3 RESULTS
3.3.1 THE STUDYPOPULATION-THE THREE STUDY GROUPS
1. 36 patients (33 males, 3 females) with Barrett's oesophagus (defined by 
endoscopic columnar lined oesophagus and intestinal metaplasia on biopsy), 
mean age 57 years (range 39-85years).
2. 32 patients (20 males, 12 females) with erosive oesophagitis, mean age 59 
years (range 35-77 years).
3. 35 patient controls (15 males, 20 females) with reflux symptoms and normal 
endoscopic appearances of the oesophagus, stomach and duodenum, mean age 
49 years (range 20-72 years).
See chart one page 63. This graph demonstrates that there is a preponderance of 
males to females in the Barrett's group with a ratio of 11:1. This is at odds with the 
literature with a quoted M:F ratio of 1.7 for patients with Barrett's oesophagus [171]. 
Chart two page 63 shows the age distribution for the entire study population (n=l 13). 
The mean age of the patients in the Barrett's and oesophagitis groups was 57 and 59 
whereas the mean age of the patients in the normal control group was 49.
The M:F ratio, and age difference between the groups in the present study will 
not have an adverse effect on the results, as a previous study of antioxidants in 
chronic pancreatitis demonstrated that antioxidant levels did not change between 
sexes or age groups [172]. Many of the previous studies discussed had not felt it 
necessary to age, and sex match controls, although we accept this is a possible 
weakness of the study.







Barrett's Oesophagitis Normal OGD
Chart one. Sex ratio by study group.
<40 40-50 50-60 60-70 70-80 >80
Chart two. Age ranges for entire group. n=103
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3.3.2 RESULTS
There are three methods for patients presenting to the endoscopy department 
for oesophagogastroduodenoscopy (OGD). First is the open access list, which means 
that the patient can be referred directly for OGD by their general practitioner. Second 
is via the outpatient department, meaning that the patient is under the care of a 
consultant within the hospital. Thirdly patients can undergo an OGD whilst being an 
inpatient within the hospital.
There is a notable difference between the mode of presentation of the three 
study groups. They will be numbered as follows. The Barrett's group was group one, 
the erosive oesophagitis group was group two, and the normal control group was 
group three. This will hold throughout the text and for the labelling of diagrams.
The most common mode of presentation within group one was via outpatients, 
whilst the most common mode of presentation within groups two and three is through 
open access lists. See chart three on page 68. This is due to the fact that in the Royal 
Glamorgan Hospital most Barrett's patients were under long term follow up and 
automatically recalled for OGD. The reason for this is that biopsies can be taken to 
look for evidence of dysplasia, which is a sign of progression to adenocarcinoma. 
These biopsies are taken according to the Seattle protocol [173]. Using a biopsy 
forceps four biopsies (one per quadrant of the oesophagus) were obtained from every 
centimetre of the Barrett segment. In all patients, at least one control biopsy specimen 
was also taken from the gastric fundus and several biopsy specimens were taken from 
any visible mucosal abnormality. For most of the patients in groups two and three this 
was their first presentation and they were referred for open access OGD via their 
general practitioner.
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The presence or absence of symptoms was ascertained for each patient. These 
will be discussed below as per study group. There were 36 patients in group one. 
Heartburn was the most common symptom with a third of the group reporting this. 
Regurgitation and dysphagia were also symptoms that were experienced by this 
group, but far fewer patients (13% and 5% respectively) had these. See chart four on 
page 68.
The 32 patients in group two complained of far more symptomatology than 
those in group one. Again heartburn was the most common, with 65% of the group 
experiencing this on a regular basis. Approximately one third of the group had 
regurgitation or epigastric pain and dysphagia was experienced by 12%. See chart five 
on page 69. The patients in group three most commonly had symptoms of heartburn 
and regurgitation, affecting over two thirds of the group. Just under one third had 
epigastric pain. See chart six on page 69.
The difference in symptoms can be explained by the fact that mucosa 
regularly exposed to acid is less sensitive to it. This has been demonstrated in a 1995 
paper from Los Angeles [174]. A naso-gastric rube was passed and saline solution 
introduced into the oesophagus. This was then switched to hydrochloric acid without 
the patient being informed, and the patients symptomatic response noted for 30 
minutes. Precipitation of pain by acid that was relieved by reinfusion of saline 
solution was a positive response. It was found that 38% of patients with no previous 
symptoms of reflux had a positive result as compared with 26% of patients known to 
have an abnormal 24-hour pH profile indicating reflux [174]. It has also been shown 
that some patients with severe symptoms may be found on endoscopy to have mild 
disease, whereas others with severe disease such as Barrett's oesophagus may have 
relatively few symptoms.
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There was no difference in the frequency or duration of symptoms between 
any of the study groups. The results were therefore examined for the entire number of 
patients recruited in the study (n=103). The frequency of heartburn symptoms varied 
widely, 70% experiencing them on a daily basis, 21% on a weekly basis and 9% on a 
monthly basis. The duration of heartburn symptoms again varied widely, with 6 % 
having them for under 3 months and 16% having them for over 36 months. The 
largest group was 24-36 months. See chart seven on page 70.
There was a wide variation in the frequency of regurgitation symptoms. 41% 
reported them daily, 41% weekly and 18% monthly. There was no difference between 
the study groups, therefore these figures are for all patients (n=103). There was again 
a marked variation in duration of regurgitation symptoms. 8% had experienced 
symptoms for less than three months and 16% had had symptoms for over 36 months. 
The largest group was again 24-36 months, with around one third of all patients 
having regurgitation having had it for this duration of time. See chart eight on page 
70.
It is noted that there was a decrease in the number of patients reporting their 
symptoms lasting for 18-24 months. See charts seven and eight on page 70. A likely 
explanation for this is that most patients first presenting to their General Practitioner 
will be empirically treated. If symptoms were still present at one year this is the point 
at which both patient and GP require a diagnostic endoscopy for clarification. In many 
patients this allowed a diagnosis to be made and treatment to commence with the 
subsequent relief of symptoms.
Just over half of the patients experiencing epigastric pain suffered it daily, one 
third had it weekly and one tenth monthly. 10% had had their symptoms for less than 
3 months and 20% had had their symptoms for over 36 months. The largest group was
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6-12 months, with just over one third of patients having their symptoms for this length 
of time. There was no difference between the groups.
One third of patients with dysphagia had symptoms daily and two thirds 
weekly. All patients had experienced symptoms for between 6 and 18 months. There 
was no difference in the frequency or duration between each group.
Other symptoms patients experienced were chest pain, belching and choking. 
There was no difference between these per study group. These symptoms were only 
experienced in a small proportion of all the patients.
Of the whole group of 103 patients 40% had an identifiable hiatus hernia. See 
chart nine on page 71. These were not found more commonly in any of the study 
groups. Of those with a hiatus hernia, 57% were small and 43% were large, although 
this was subjective for operator interpretation.
The degree of inflammation of the oesophagus in the 32 patients in group two 
was assessed using the Los Angeles classification [175]. This is as follows:-
Grade A. Mucosal breaks confined to the mucosal fold, each <5mm.
Grade B. At least one mucosal break >5mm confined to the mucosal fold but not
continuous between folds. 
Grade C. Mucosal breaks that are continuous between the tops of mucosal folds but
not circumferential. 
Grade D. Extensive mucosal breaks engaging at least 75% of the oesophageal
circumference.
31% of these patients had grade A inflammation, 59% had grade B inflammation 








Group 1 Group 2 Group 3
Chart three. Referral source by study group.
IP= Inpatient OP= Outpatient OA— Open Access
H/B Regurg. E. Pain Dysphagia
Chart four. Percentage of symptoms experienced by patients in group one. (n=36)




H/B Regurg. E. Pain Dysphagia
Chart five. Percentage of symptoms experienced by patients in group two. (n=32)
H/B= Heartburn Regurg. = Regurgitation E.Pain= Epigastric Pain.
Percentage 
of Patients
H/B Regurg. E. Pain Dysphagia
Chart six. Percentage of symptoms experienced by patients in group three. (n=35)
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Chart seven. Duration of heartburn for all patients. (n=103)
No. of 
Patients
<3 3-6 6-12 12-18 18-24 24-36 >36 
months months months months months months months





Chart nine. Presence of hiatus hernia for all patients. (n=103)
No. of 
Patients
Chart ten. Los Angeles Classification of oesophagitis in group two.
(n=32)
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3.3.3 ANTIOXIDANTS IN BARRETT'S GROUP/CONTROLS
In this study deficiencies of four antioxidants were found in the Barrett's 
group as compared to one or other control group. See table one below. The serum 
levels of Vitamin C, p-cryptoxanthine, xanthophyll, and selenium were reduced in the 











































Table One. Results of serum Vitamin C, ft-cryptoxanthine, xanthophyll, and 
selenium for Groups One, Two, and Three. Values shown are means, and 95%
confidence intervals.
Statistical analysis was performed using the ANOVA test. This is similar to 
the independent t-test but allows comparison between more than two conditions. A 
significant p-value will indicate that there is an effect somewhere between the groups, 
but will not indicate where the effect lies [176]. Where the ANOVA has shown a 
significant p-value then follow-up t-tests on both pairs were undertaken. 




























































Table Two. Serum levels of those antioxidants not reduced in either of the 
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The clinical observations that were undertaken showed there is a difference in 
the severity of symptoms reported in the three study groups. The Barrett's group 
(group one) experienced far fewer symptoms than the oesophagitis group (group two) 
who in turn experienced less than the control group (group three). The difference in 
symptoms can be explained by the fact that mucosa regularly exposed to acid is less 
sensitive to it. This has been demonstrated in a 1995 paper from Los Angeles [174]. A 
naso-gastric tube was passed and saline solution introduced into the oesophagus. This 
was then switched to hydrochloric acid without the patient being informed, and the 
patients symptomatic response noted for 30 minutes. Precipitation of pain by acid that 
was relieved by reinfusion of saline solution was a positive response. It was found 
that 38% of patients with no previous symptoms of reflux had a positive result as 
compared with 26% of patients known to have an abnormal 24-hour pH profile 
indicating reflux. It has also been shown that patients with severe disease such as 
Barrett's oesophagus may have relatively few symptoms [174].
It was noted that there was a decrease in the number of patients reporting their 
symptoms lasting for 18-24 months. A likely explanation for this is that most patients 
first presenting to their General Practitioner with reflux symptoms will be empirically 
treated with proton pump inhibitors in order to reduce the amount of acid in their 
stomachs and hence the reflux. If symptoms are still present at one year this is the 
point at which both patient and GP require a diagnostic endoscopy for clarification. In 
many patients this will allow a diagnosis to be made and appropriate treatment to 
commence with the subsequent relief of symptoms.
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Our main findings were that patients with Barren's oesophagus had 
significantly lower serum concentrations of the antioxidants vitamin C, 0- 
cryptoxanthine, selenium, and xanthophylls compared to patient controls with little or 
no oesophageal injury.
A dietary history was not taken as part of this study. There have been many 
dietary inventory studies published in the literature, which have been discussed 
previously in this work, and it was not felt necessary to replicate that research. On the 
basis of these results it is highly likely that the subjects in our study found to have 
decreased serum levels of antioxidants have a poor intake of antioxidants in the form 
of fresh fruit and vegetables in their diet. Two of the three studies quoted in this 
research designed to examine the links between antioxidants and Barrett's have taken 
dietary information into account, and indeed have proven a direct relationship 
between the dietary content and serum levels of antioxidants [15, 123]. Our study was 
designed to investigate whether patients with Barrett's have low serum antioxidant 
levels, as compared to controls with both reflux induced oesophageal damage, and 
normal oesophageal mucosa.
Antioxidants may act as reverse acute phase reactants [170]. This means that 
patients with ongoing ill health or occult inflammatory processes will have a higher 
turnover of antioxidants hence resulting in reduced serum levels. So as to ensure our 
results were not biased by including patients with occult illness or inflammation these 
subjects were excluded on the basis of either a raised C Reactive Protein (CRP) 
(>10mg/L) or hypoalbuminaemia (<32mg/L).
There are two possible explanations for our findings. The first is that patients 
developing Barrett's oesophagus also develop a concurrent deficiency in serum 
antioxidants. A second and more likely explanation in the light of the previously
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discussed dietary inventory studies is that patients with a pre-existing antioxidant 
deficiency develop Barrett's oesophagus and in turn are at risk of adenocarcinoma.
It is postulated that Barrett's develops as a result of reflux disease, in which 
the injured squamous epithelium heals through a metaplastic process. This results in 
an abnormal columnar epithelium lining the oesophagus [26]. As antioxidant 
deficiency results in the increased processes responsible for the development of 
malignancies [94] and Barrett's oesophagus is a pre-malignant condition [33] it is 
possible that the antioxidant deficient patient is unable to protect the epithelium from 
this process and is therefore more likely to develop Barrett's oesophagus as a 
consequence of their reflux.
At present there is a relative paucity of information in the literature relating to 
antioxidants and Barrett's oesophagus. Two studies from one institution (of patients 
with Barrett's oesophagus) identified low levels of selenium in Barrett's patients who 
progressed onto adenocarcinoma [123, 125]. Rudolph etal [125] evaluated selenium 
levels in patients with Barrett's oesophagus enrolled in a surveillance programme. 
The authors found that low selenium levels were associated with an increased risk of 
progression to high-grade dysplasia. Thus these two studies support the hypothesis 
that antioxidant deficiency pre-dates and possibly predisposes to the development of 
Barrett's and hence adenocarcinoma.
Moe etal [123] found that a decreased dietary selenium intake resulting in 
decreased serum levels increased the risk of progression of Barrett's oesophagus to 
adenocarcinoma. A number of studies have evaluated retrospectively antioxidant 
intake in patients with oesophageal adenocarcinoma [10-14]. These reports suggested 
a lower incidence of oesophageal adenocarcinoma for diets rich in citrus fruits, certain 
vegetables and several antioxidants, notably Vitamin C and p-Carotene, therefore
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suggesting a protective effect of such a diet. These results show that patients with a 
poor antioxidant diet have developed adenocarcinoma. This would further support our 
hypothesis that the antioxidant deficient patient is at a higher risk of developing 
Barrett's oesophagus as a result of reflux disease.
The present results add support to the thesis that antioxidants protect the 
oesophageal mucosa from metaplastic change in response to reflux. It is possible that 
elevated serum antioxidant levels protect mucosa inflamed by reflux from DNA 
damage, metaplastic change, and the subsequent development of Barrett's 
oesophagus.
Is there any therapeutic potential for our observations? For example should 
antioxidant supplementation be recommended in order to prevent the development of 
Barrett's oesophagus and hence adenocarcinoma? Previously discussed epidemiologic 
studies have shown that cancer incidence is higher in areas where soil selenium is low 
[145]. Furthermore the epidemiology of squamous carcinoma in high incidence 
regions of China supports an association with antioxidant deficiency [177], as does 
the epidemiology of adenocarcinoma in China [14]. Lastly, large scale antioxidant 
supplementation studies have demonstrated a reduction in the risk of malignant 
transformation of squamous dysplasia [154]. It is an appealing concept that the same 
will hold true for glandular dysplasia and adenocarcinoma, although larger scale 
research on the subject is necessary. Whilst it was an attractive proposition to carry 
out supplementation of antioxidants in this study, it was unfortunately not deemed 
possible due to limitations of time, funding and resources.
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3.5 CONCLUSION
1. Poor nutrition and the resulting antioxidant deficiencies are a risk factor in 





bcl-2, bax AND p53 IN OESOPHAGEAL
TUMOURS
4.1 INTRODUCTION
Patients receiving neoadjuvant chemoradiotherapy for treatment of 
oesophageal carcinoma are divided into two groups. A proportion of patients will 
respond to the treatment, whilst others will not. An elevated ratio of bcl-2 to bax in 
prostate cancer has been shown to predict an increased risk of the cancer failing to 
respond to radiotherapy [82]. Over-expression of p53 has been shown to decrease the 
response to chemoradiotherapy in oesophageal carcinoma [75], and forced expression 
of the wild-type p53 gene has been shown to increase the sensitivity to 
chemoradiotherapy [77].
This study was designed to determine whether a tumours response to 
chemoradiotherapy can be predicted by expression of bcl-2, bax and p53. 
Chemoradiotherapy is associated with significant side effects [45-47]. It was also of 
interest whether the patients whose tumour had a good response to chemoradiotherapy 
would have more sensitive normal tissues. This would manifest in increased post­ 
operative complications because of increased lung and cardiac damage from the 
treatment. The post-operative complications were therefore compared to the patients' 
response to chemoradiotherapy.
4.2 METHODOLOGY
4.2.1 COLLECTION OF SAMPLES
Full ethical approval was granted by the Bro-Taf Local Research and ethics 
committee (Protocol #03/5133) before beginning the project. The study group 
comprised of patients having neoadjuvant chemoradiotherapy prior to a planned 
oesophagectomy. There were twelve patients in the study group. A power sample test 
was not carried out for several reasons. There are no known results on which to base
82
such a calculation, in addition to this the results are not expressed numerically but in 
terms of low, moderate or high expression. This was corroborated by the fact that 
none of the papers I have quoted had determined a sample size. Finally we were only 
able to obtain funding for a limited number of slides to be processed. This study 
therefore must be viewed strictly as a pilot study.
Ten of the subjects had proven adenocarcinoma and two had proven squamous 
cell carcinoma of the oesophagus. The diagnosis was confirmed by histological 
examination of biopsies taken at the time of endoscopy. If a clinically suspicious area 
is seen in the oesophagus or stomach at the time of endoscopy then multiple samples 
of this are taken with biopsy forceps passed down a channel of the endoscope for this 
purpose. These samples are then examined by an experienced pathologist. There were 
no data available as to the sensitivity and specificity of these biopsies. It is certainly 
approaching 100%, as the clinical implications of a false positive or negative are 
enormous. Sample sizes of n=l are treated and offered major surgery in the form of an 
oesophagectomy in surgical practice on a daily basis on the results of these biopsies. 
There is scope for a false negative result to occur, this is due to the rumour itself not 
being biopsied, as often there is inflammatory tissue associated with it. If this occurs, 
and there is a strong clinical suspicion the endoscopy, and biopsies are repeated.
Data regarding demographics were obtained from the Royal Glamorgan 
Hospital database. Clinical and pathological reports were similarly obtained. Three 
cycles of cisplatin and 5-fluorouracil together with concurrent radiotherapy were 
administered in Velindre hospital. The original biopsy specimens from the tumours 
were obtained from the department of pathology of the hospital in which the tumour 
was diagnosed, and taken to the University Hospital of Wales where the 
immunohistocytochemistry analysis was performed.
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4.2.2 IMMUNOHISTOCYTOCHEMISTRY ANALYSIS
All analysis was carried out in the department of Pathology at the University 
Hospital of Wales. All slides were stained on Autostainer (Dakocytomation). Mouse 
monoclonal antihuman bcl-2 antibody was used at 1/100 dilution Code M0887 
(Dakocytomation). DO7 monoclonal antibody against p53 protein was used at 1/200 
dilution Code M 7001 (Dakocytomation). The slides were blocked for endogenous 
biotin (Vector lab SP-2001), and endogenous peroxidase (Dakocytomation). The 
antigen retrieval protocol was 600ml of 10 mmol EDTA pH 7.0, 20 minutes of 
microwave at 800 watts with five minutes standing time.
Formalin fixed paraffin processed sections were cut at four microns and 
floated onto superfrost plus electrostatically charged slides. These were then heated at 
60° Centigrade overnight. Sections were dewaxed in Xylene, dehydrated in alcohol 
and placed in running tap water. The slides were then placed into antigen retrieval 
solution and microwaved in a covered container, flushed with running tap water and 
placed into deionised water. They were placed into a wash buffer for five minutes 
before being placed onto the autostainer. Immunoperoxidase slides were 
counterstained with Haematoxylin, dehydrated in alcohol, cleared in xylene and 
mounted with a coverslip.
An Olympus microscope model BH-2 was used to examine the slides. Firstly 
there were two control slides. The purpose of these was to demonstrate a positive 
result for bcl-2 and p53. For bcl-2 a slide of tonsil was used, and for p53 a slide of 
colorectal cancer was used. Tonsillar tissue has a high expression of bcl-2 and 
colorectal cancer has a high expression of p53. [178]
Wild-type p53 protein mediates apoptosis by directly activating the expression 
of bax and indirectly inhibiting the expression of bcl-2 [69, 70]. If the p53 is mutated
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this effect will be lost. Forced expression of wild-type p53 has been shown to increase 
the sensitivity to chemoradiotherapy [77]. Therefore if the tumour has a higher 
expression of wild-type p53 it may be expected to be more sensitive to 
chemoradiation. Wild-type p53 is not demonstrated with immunohistocytochemistry, 
whereas mutated p53 is. Therefore the higher the expression of p53 under the 
microscope the higher the ratio of mutated p53 in the specimen. See figures three and 
four on page 86.
For each patient three slides were made. Firstly a blank slide to ensure any 
positive results were due to the immunohistocytochemical staining for bcl-2 and p53. 
Secondly a slide was stained for bcl-2, and the third slide was stained for p53. Each 
slide was reviewed to determine whether it was positive for bcl-2 or p53. It is not 
possible to determine the sensitivity and specificity for the two reagents for bcl-2 or 
p53. The reason for this is that in order to determine the sensitivity and specificity of a 
test, the results must be measured against a known independent marker. As yet an 
independent marker of expression of bcl-2, and bax in tumour cells has not been 
found. There is not a quoted sensitivity or specificity in any of the published articles 
on this subject, and this is certainly an area where there is a gap in the knowledge.
If the slide was positive the degree of expression was ascertained. If the 
expression was visible on low power (xlO) the biopsy was said to be strongly 
positive. If visible at medium power (x20) then the biopsy was moderately positive, 
and if high power (x40) was needed the biopsy was said to be weakly positive, hi 
order to maximise the accuracy, and reproducabiliy of the results, all were repeated 
after a certain time interval, and all results were verified by a second party. 
Additionally the results were verified by a histopathologist experienced in this field.
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Figure Four. Colorectal cancer control slide to show positive staining for p53.
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4.2.3 MORBIDITY AFTER NEOADJUVANT THERAPY
A retrospective review of the twelve patients' notes was carried out in order to 
determine whether those patients with a good response to the neoadjuvant treatment 
also had increased morbidity and mortality, as result of their tissues being sensitive to 
the treatment. The information collected was :-
1. Time the patient was ventilated on one lung during surgery.
2. Blood loss during theatre.
3. Length of stay in intensive care or high dependency unit post operatively 
and total inpatient stay.
4. Number of days the patient received antibiotics post operatively.
5. Inpatient morbidity/mortality.
4.3 RESULTS
4.3.1 bcl-2, p53 AND RESPONSE TO CHEMORADIOTHERAPY
The results are as shown in the following tables on page 88. There are two 
tables. The first shows the results for the patients having had a good response to 
chemoradiotherapy. The second table outlines the results for the patients who did not 
respond to chemoradiotherapy. In the column headed chemoradiotherapy (CRT) 
response is the histological response to the chemoradiotherapy in the resected cancer 
specimen. This was judged by the pathologist reporting the surgically resected 
specimen. Complete response showed absence of residual cancer. Near complete 
response was characterised by the presence of rare residual cancer cells, and 
significant residual disease was characterised by residual cancer outgrowing fibrosis. 




























































Table Four. Expression ofbcl-2 andpSS in those patients having a poor response to
chemoradiotherapy.
The figures on page 89 show two of the slides. Figure six shows an example of p53 
positivity. The positive p53 staining can clearly be seen in the epithelial cells. Figure 
seven shows an example of a slide that is bcl-2 negative, although there is some 
functional expression demonstrated within the inflammatory cells. However there is 
no expression ofbcl-2 within the epithelial cells.
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Figure Five. Slide ofoesophageal cancer to show p53 positivity.
Figure Six. Slide ofoesophageal cancer to show bcl-2 negavivity. Functional 
expression in inflammatory cells only.
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4.3.2 MORBIDITY AFTER CHEMORADIOTHERAPY
Twelve patients had neoadjuvant chemoradiation before oesophagectomy. 
Four cycles of cisplatin were given every three weeks plus continuous infusion of 
5-fluorouracil. Cycles three and four were given concurrently with 45 Gy external 
beam radiotherapy to the mediastinum delivered in 25 fractions over five weeks [44]. 
Radiotherapy to the mediastinum has been shown to cause cardiac damage [47], and 
pnemonitis [45, 46], which can result in increased post-operative complications [46].
Ten patients had adenocarcinoma and two patients had squamous cell 
carcinoma. Of these twelve patients five had a good response to the treatment (no 
residual tumour histologically in the specimen in one case and rare residual cancer 
cells in four cases) and seven had a poor response (tumour cells still present 
histologically). See Tables five and six on page 91. There was no difference between 
the ages and the histological type of tumour between the groups. There were no 
inpatient deaths in the group having a poor response to chemoradiation. There was 
one inpatient death in the group who had a good response. This death was due to adult 
respiratory distress syndrome, sepsis and pulmonary odema.
60% of patients had a complication in the group having a good response, 
compared to 42% having a poor response. The patients in the group responding well 
to chemoradiation had a far longer stay on both ITU and HDU and total hospital stay 
21.5 days and 26.5 days, as compared to 9.5 days and 24.5 days for the group having 
a poor response. The time the patient was ventilated on one lung was the same for 
both groups, the group responding poorly had greater blood loss of 1 lOOmls 
compared to 550 mis. The good responders had a far longer duration of antibiotic 
therapy. This was 22 days as compared to 7.5 days. The decision to continue 





























































































































































































Table Six. Patients having poor response to chemoradiation.
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4.4 DISCUSSION
Over expression of bcl-2 has been found in 72 % of Barrett's metaplastic 
lesions and in 100% of Barrett's with low grade dysplasia [72], and an elevated ratio 
of bcl-2 to bax in prostate cancer has been shown to predict an increased risk of the 
cancer failing to respond to radiotherapy [82]. Over expression of p53 has been shown 
to decrease the response to chemoradiotherapy [75], and forced expression of wild- 
type p53 gene can increase the sensitivity to chemoradiotherapy [77]. It has been 
shown that patients receiving neoadjuvant chemoradiotherapy may be at greater risk 
of infections [62], and have a reduction in physical performance which in turn can 
predict the subsequent postoperative risk [63].
This study was therefore set up to determine whether it would be possible in 
the clinical setting to determine the levels of bcl-2, bax and p53 in oesophageal 
tumours and use this information to predict whether the patient would be likely to 
respond to chemoradiotherapy. It was expected patients responding would have high 
levels of bax, and a bcl-2 to bax ratio favouring bax expression. Those not responding 
would have high levels of bcl-2, and p53 (as immunohistocytochemistry for p53 
identifies mutated p53 only, and not wild-type p53). If it were possible to identify the 
patients not likely to respond they would be spared toxic treatment, and the possible 
increased post-operative complications associated with this.
It was discovered whilst beginning analysis that the antibody against the bax 
protein was not being expressed. All the oesophageal tumour biopsies being analysed 
had previously been fixed in paraffin, as part of the routine preparation of histological 
slides. Unfortunately it was realised the bax antigen, was undetectable in the paraffin 
sections. To rectify this a catalysed amplification system was necessary in order to 
enhance expression. This is the most sensitive of all the immunohistochemical
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staining procedures, and involves the consecutive application of primary antibody, 
secondary link antibody, streptavidin-biotin complex, biotinylated tyramide, 
streptavidin peroxidase conjugate, and finally DAB substrate chromogen [178]. There 
were two reasons for the decision not to proceed with amplification. Firstly the ratio 
of bcl-2 to bax was more crucial than the individual expression of each. 
Amplification would mean the expression of bax being highly amplified as compared 
to the expression of bcl-2, rendering the ratio of one to the other impossible. Secondly 
purchasing the extra reagents would have imparted unforeseen substantial extra costs, 
with no guarantee of success. It was therefore decided to abandon the determination 
of bax expression, and hence the ratio of bcl-2 to bax. The study objectives were 
modified to ascertaining the expression of bcl-2 and p53 in the oesophageal tumour 
biopsies and comparing these to the response to chemotherapy.
Patients with oesophageal cancer treated with neoadjuvant chemoradiotherapy 
are divided into two distinct groups. There are those who respond well to treatment 
and have little or no residual tumour at operation, and there are those who do not 
respond and have residual disease. There was no obvious difference between the two 
groups in terms of expression of p53 or bcl-2. It is possible a difference exists, but 
very large numbers may be needed in order to demonstrate this. Of the papers 
identified on this subject several [76, 80, 81] identified no correlation between p53, 
and bcl-2 expression, and the response to chemotherapy.
The above results obtained suggest that patients having a good 
histological response to chemoradiation (because their tumours are sensitive to the 
treatment) may also have normal tissues which are sensitive, so resulting in an 
increase in mortality and morbidity. The patients in our series responding well to 
chemoradiotherapy had increased inpatient mortality, morbidity, ITU/HDU, and total
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inpatient stay, and antibiotic days. The group responding poorly to cheraoradiotherapy 
had an increased blood loss in theatre, this is most likely due to the residual tumour 
being more difficult to dissect. It has been shown in the literature that patients having 
neoadjuvant treatment may be at increased risk of infections and complications 
postoperatively [62, 63], in line with our findings.
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4.5 CONCLUSIONS
1. Sadly because of unforseen methological problems, the results from the 
present study did not confirm the studies that have been highlighted in the 
review. Therefore as a result of this confounding variable no valid conclusion 
could be arrived at.
2. From the results of our small review it may be that patients having a good 
response to neoadjuvant chemotherapy have a higher rate of complications 




DIRECTIONS FOR FUTURE RESEARCH
5.1 SUMMARY OF FINDINGS
1. The hypothesis was that patients with Barrett's oesophagus will have lower 
serum levels of antioxidants (Selenium, Copper, Zinc, Vitamins A, C, E, P- 
cryptoxanthine, and xanthophyll) than control groups. This hypothesis was 
found to be true with the serum levels of (3- Cryptoxanthine, Vitamin C, 
selenium, and xanthophyll being significantly reduced in patients with 
Barrett's oesophagus as compared to control groups.
2. The hypothesis was that patients who have a good pathological and clinical 
response to neoadjuvant chemoradiotherapy will have a lower level of the 
apoptosis inhibiting oncogene bcl-2 in the rumour cells, and a bcl-2 to bax 
ratio favouring bax expression. The expression of bcl-2 and bax is a very 
exciting area, however the study because of unforeseen methological problems 
was not able to endorse the hypothesis.
3. The hypothesis was that the patients responding well to neoadjuvant therapy 
will have a high level of the bcl-2 inhibiting protein wild type p53. 
Unfortunately our results were unequivocal and we were unable to prove this 
hypothesis with our study.
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5.2 DIRECTIONS FOR FUTURE RESEARCH
1. The next step on from this thesis would be a much larger-multi centred trial 
looking into the serum levels of antioxidants in patients with Barrett's 
oesophagus.
2. The trial described above could then be followed on with a supplementation 
trial whereby the diets of subjects with Barrett's oesophagus are supplemented 
with different antioxidants in particular selenium and vitamin C in order to 
ascertain whether supplementation could stop the progression to 
adenocarcinoma.
3. It would be very interesting to measure the antioxidant levels in patients 
having neoadjuvant chemoradiotherapy, in order to measure if there is a 
difference between those groups having a complete pathological response, and 
those having a poor pathological response to the treatment.
4. The use of bcl-2, bax, and p-53 being used as a responsive indicator to 
chemotherapy has major clinical implications. It would therefore be of 




1. Blot WJ, Devessa.SS, Kneller RW, Fraumeni JF Jr., Rising incidence of
adenocarcinoma of the esophagus and gastric cardia. JAMA, 1991. 265(10): 
p. 1287-9.
2. el-Serag, H.B., The epidemic ofesophageal adenocarcinoma.
Gastroenterology Clinics of North America, 2002. 31(2): p. 421-40.
3. Brown LM, Swanson CA, Gridley G, Swanson GM, Silverman DT,
Greenberg RS, Hayes RB, Schoenberg JB, Pottern LM, Liff JM, Schwartz 
AG, Hoover R, Fraumeni JF Jr., Dietary factors and the risk ofsquamous cell 
esophageal cancer among black and -white men in the United States. Cancer 
Causes & Control, 1998. 9(5): p. 467-74.
4. Launoy G, Milan C, Day NE, Pienkowski MP, Gignoux M, Faivre J., Diet and 
squamous-cell cancer of the oesophagus: a French multicentre case-control 
study. International Journal of Cancer, 1998. 76(1): p. 7-12.
5. Gao YT, McLaughlin J, Gridley G, Blot WJ, Ji BT, Dai Q, Fraumeni JF Jr., 
Risk factors for esophageal cancer in Shanghai, China. II. Role of diet and 
nutrients. International Journal of Cancer, 1994. 58(2): p. 197-202.
6. Cheng KK, Day NE., Nutrition and esophageal cancer. Cancer Causes & 
Control, 1996. 7(1): p. 33-40.
7. Brown LM, Blot WJ, Schuman SH, Smith VM, Ershow AG, Marks RD,
Fraumeni JF Jr., Environmental factors and high risk ofesophageal cancer 
among men in coastal South Carolina. Journal of the National Cancer 
Institute, 1988. 80(20): p. 1620-5.
8. Terry P, Lagergren J, Ye W, Nyren O, Wolk A., Antioxidants and cancers of 
the esophagus and gastric cardia. International Journal of Cancer, 2000. 
87(5): p. 750-4.
9. Garidou A, Tzonu A, Lipworth L, Signorello LB, Kalapothaki V,
Trichopoulos D., Life-style factors and medical conditions in relation to 
esophageal cancer by histologic type in a low-risk population. International 
Journal of Cancer, 1996. 68(3): p. 295-9.
10. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari 
P, Ahrned A, Day NE., A case-control study ofoesophageal adenocarcinoma 
in women: a preventable disease. Journal of Cancer, 2000. 83(1): p. 127-32.
11. Zhang ZF, Kurtz.RC, Yu GP, Sun M, Gargon N, Karpeh M Jr, Fein JS, Harlap 
S., Adenocarcinomas of the esophagus and gastric cardia: the role of diet. 
Nutrition & Cancer, 1997. 27(3): p. 298-309.
12. Tzonou A, Lipworth.L, Garidou A, Signorello LB, Lagiou P, Hsieh C,
Trichopoulos D., Diet and risk ofesophageal cancer by histologic type in a 
low-risk population. International Journal of Cancer, 1996. 68(3): p. 300-4.
100
13. Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, 
Greenberg RS, Silverman DT, Pottern LM, Hayes RB, Shwartz AG., 
Adenocarcinoma of the esophagus: role of obesity and diet. Journal of the 
National Cancer Institute, 1995. 87(2): p. 104-9.
14. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, Fraumeni JF 
Jr, Blot WJ, Dong ZW, Taylor PR., Prospective study of serum selenium levels 
and incident esophageal and gastric cancers. Journal of the National Cancer 
Institute, 2000. 92(21): p. 1753-63.
15. Fountoulakis A, Martin.IG, White KLM, Dixon MF, Cade JE, Sue-Ling HM, 
Wild CP., Plasma and Esophageal Mucosal Levels of Vitamin C: Role in the 
Pathogenesis and Neoplastic Progression of Barren's Esophagus. Digestive 
Diseases and Sciences, 2004. 49(6): p. 914-919.
16. Underwood, General and Systematic Pathology. , ed. Underwood. 1992: 
Churchill Livingstone. 815.
17. Aird, The newAird's companion in surgical studies, ed. Y.A. Burnard KG. 
1992: Churchill Livingstone. 541.
18. Vaughan TL, Davis S, Kristal A, Thomas DB., Obesity, alcohol, and tobacco 
as risk factors for cancers of the esophagus and gastric cardia: 
adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiology, 
Biomarkers & Prevention, 1995. 4(2): p. 85-92.
19. Mathers CD, Boshi-Pinto C, Lopez AD, Murray CJL., Cancer incidence,
mortality and survival by site for 14 regions of the world. 2001, World Health 
Organisation.
20. Vizcaino AP, Moreno V, Lambert R, Parkin DM., Time trends incidence of 
both major histologic types of esophageal carcinomas in selected countries, 
1973-1995[erratum appears in Int J Cancer 2002 Oct 20;101(6):599]. 
International Journal of Cancer, 2002. 99(6): p. 860-8.
21. Kocher HM, Linklater K, Patel S, EIIul JP., Epidemiological study of
oesophageal and gastric cancer in south-east England. British Journal of 
Surgery, 2001. 88(9): p. 1249-57.
22. Kubo A, Corley DA, Marked regional variation in adenocarcinomas of the 
esophagus and the gastric cardia in the United States. Cancer, 2002. 95(10): 
p. 2096-102.
23. Bareiss D, Stabenow R, Muller R, Eisinger B, Stegmaier C, Daubler P, Zeitz 
M, Scherubl H., [Current epidemiology of carcinoma of the esophagus and 
cardia in Germany]. Deutsche Medizinische Wochenschrift, 2002. 127(25- 
26): p. 1367-74.
101
24. Lagergren J, Increased incidence of adenocarcinoma of the oesophagus and 
cardia. Reflux and obesity are strong and independent risk factors according 
to the SECC study. Lakartidningen, 2000. 97(16): p. 1950-3.
25. Lagergren J, Bergstrom R, Lindgren A, Nyren O., Symptomatic
gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New 
England Journal of Medicine, 1999. 340(11): p. 825-31.
26. Spechler S, Barren's esophagus and esophageal adenocarcinoma:
pathogenesis, diagnosis, and therapy. Medical Clinics of North America, 
2002. 86(6): p. 1423-45.
27. Tileston W, Peptic Ulcer of the Oesophagus. Am J Med Sci, 1906. 132: p. 
240-265.
28. Barrett N, Chronic Peptic ulcer of the oesophagus, and oesophagitis. BRitish 
Journal of Surgery, 1950. 38: p. 175-182.
29. Allison PR, Johnstone AS, The Oesophagus lined with gastric mucous 
membrane. Thorax, 1953. 8: p. 87-101.
30. Barrett N, The lower oesophagus lined by columnar epithelium. Surgery, 
1957. 41: p. 881-894.
31. Spechler SJ, Antonioloi DA, Wang HH, Goyal RK., Prevalence of metaplasia 
at the gastro-oesophageal junction. Lancet, 1994. 344: p. 1533-6.
32. Winters C Jr, Spurling TJ, Chobanian SJ, et al., A prevalent, occult
complication of gastrooesophageal reflux disease. Gastroenterology, 1987. 92: 
p. 118-24.
33. Spechler S, Managing Barren's Oesophagus. BMJ, 2003. 326(7395): p. 892- 
893.
34. Chak A, Canto MI, Cooper GS, Isenberg G, Willis J, Levitan N, dayman J, 
Forastiere A, Heath E, Sivak MV Jr., Endosonographic assessment of 
multimodality therapy predicts survival of esophageal carcinoma patients. 
Cancer, 2000. 88(8): p. 1788-95.
35. Pye JK, Crumplin M, Charles J, Kerwat R, Foster ME, Biffin A, One-year
survey of carcinoma of the oesophagus and stomach in Wales. British Journal 
of Surgery, 2001. 88: p. 278-285.
36. Cariati A, Casano A, Campagna A, Cariati E, Pescio G., Prognostic factors 
influencing morbidity and mortality in esophageal carcinoma. Revista do 
Hospital das Clinicas, 2002. 57(5): p. 201-4.
37. Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP., Surgical 
management of and long-term survival after adenocarcinoma of the cardia. 
British Journal of Surgery, 2002. 89(9): p. 1156-63.
102
38. Watanabe M, Kuwano H, Araki K, Kawaguchi H, Saeki H, Kitamura K, Ohno 
S, Sugimachi K., Prognostic factors in patients with submucosal carcinoma of 
the oesophagus. British Journal of Cancer, 2000. 83(5): p. 609-13.
39. Tachibana M, Kinugasa S, Dhar DK, Shibakita M, Ohno S, Masunaga R, 
Kotoh T, Kubota H, Nagasue N., Prognostic factors in node-negative 
squamous cell carcinoma of the thoracic esophagus. International Journal of 
Surgical Investigation, 2000. 1(5): p. 389-95.
40. Natsugoe S, Yoshinaka H, Shimada M, Sakamoto F, Morinaga T, Nakano S, 
Kusano C, Baba M, Takao S, Aikou T., Number of lymph node metastases 
determined by presurgical ultrasound and endoscopic ultrasound is related to 
prognosis in patients with esophageal carcinoma. Annals of Surgery, 2001. 
234(5): p. 613-8.
41. Bazarbashi S, Rahal M, Raja MA, El Weshi A, Pai C, Ezzat A, Ajarim D,
Memon M, Al Fadda M., A pilot trial of combination cisplatin, 5-fluorouracil 
and interferon-alpha in the treatment of advanced esophageal carcinoma. 
Chemotherapy, 2002. 48(4): p. 211-6.
42. Ahn JH, Kang YK, Kirn TW, Baring H, Chang HM, Kang WC, Kirn WK, Lee 
JS, Park JS., Nephrotoxicity ofheptaplatin: a randomized comparison with 
cisplatin in advanced gastric cancer. Cancer Chemotherapy & Pharmacology, 
2002. 50(2): p. 104-10.
43. Cho EK, Lee WK, Lim do Y, Bang SM, Park DK, Park YH, Kwon OS, Choi 
DJ, Shin DB, Lee JH, Lee TH., Epirubicin, cisplatin, and protracted venous 
infusion of 5-fluorouracil for advanced gastric carcinoma. Journal of Korean 
Medical Science, 2002. 17(3): p. 348-52.
44. Crosby TDL, Brewster A, Borley A, Perschky L, Kehagioglou P, Court J, 
Maughan TS., Definitive chemoradiation in patients with inoperable 
oesophageal cancer. British Journal of Cancer, 2004. 90: p. 70-75.
45. Park KJ, Chung JY, Chun, MS, Sun JH, Radiation-induced lung disease and 
the impact of radiation methods on imaging features. Radiographics, 2000. 
20(1): p. 83-98.
46. Abou-Jawade RM, Mekhail T, Adelstein DJ, Rybicki LA, MAzzone PJ, Caroll 
MA, Rice TW., Impact of induction concurrent chemoradiotherapy on 
pulmonary function and postoperative acute respiratory complications in 
esophageal cancer. Chest, 2005. 128(1): p. 250-5.
47. Gaya AM, Aahford RF, Cardiac complications of radiation therapy. Clin 
Oncol, 2005. 17(3): p. 153-9.
48. Malmaner R, Fenlon D, Preoperative chemotherapy for resectable thoracic 
esophageal cancer. Cochrane Database of Systematic Reviews, 2001 (1): p. 
CD001556.
103
49. Slater MS, Holland J, Faigel DO, Sheppard BC, Deveney CW., Does
neoadjuvant chemoradiation downstage esophageal carcinoma? American 
Journal of Surgery, 2001. 181(5): p. 440-4.
50. Heise JW, Keep H, Frieling T, Sarbia M, Hartmann KA, Roller HD., Expense 
and benefit of neoadjuvant treatment in squamous cell carcinoma of the 
esophagus. BMC Cancer, 2001. 1(1).
51. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, 
Roussel A, Jacob JH, Segol P, Samama G., Pathologic assessment of tumor 
regression after preoperative chemoradiotherapy of esophageal carcinoma. 
Clinicopathologic correlations. Cancer, 1994. 73(11): p. 2680-6.
52. Dunne B, Reynolds JV, Mulligan E, Kelly A, Griffin M., A pathological study 
of tumour regression in oesophageal adenocarcinoma treated with 
preoperative chemoradiotherapy [comment]. Journal of Clinical Pathology, 
2001. 54(11): p. 841-5.
53. Shiozaki H, Yano M, Neoadjuvant chemoradiotherapy in patients with
surgically treated T4 esophageal squamous cell carcinnoma. Nippon Geka 
Gakkai Zasshi. Journal of Japan Surgical Society, 2002. 103(3): p. 284-9.
54. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, 
Bonavina L, Peracchia A., Only pathologic complete response to neoadjuvant 
chemotherapy improves significantly the long term survival of patients with 
resectable esophageal squamous cell carcinoma: final report of a randomized, 
controlled trial of preoperative chemotherapy versus surgery alone. Cancer, 
2001. 91(11): p. 2165-74.
55. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Henessey TP., A 
comparison ofmultimodal therapy and surgery for esophageal 
adenocarcinoma. New England Journal of Medicine, 1996. 335(7): p. 462-7.
56. Medical Research Council Oesophageal Cancer Working Group, Surgical
resection with or without preoperative chemotherapy in oesophageal cancer: 
a randomised controlled trial. Lancet, 2002. 359(9319): p. 1727-33.
57. Urschel JD, Vasan H, A meta-analysis of randomised controlled trials that 
compared neoadjuvant chemoradiation and surgery to surgery alone for 
resectable oesophageal cancer. Am J Surg, 2003. 185(6): p. 538-43.
58. Chan AC, Lee DW, Griffith JF, Leung SF, Lam YH, Lam CC, Lau JY, Ng 
EK, Chung SC., The clinical efficacy of neoadjuvant chemotherapy in 
squamous esophageal cancer: a prospective nonrandomized study of pulse 
and continuous-infusion regimens with Cisplatin and 5- 
Fluorouracil.[comment]. Annals of Surgical Oncology, 2002. 9(7): p. 617-24.
104
59. Eguchi R, Ide H, Nakamura T, Hayashi K, Ohta M, Okamoto F, Itoh H,
Takasaki K., Analysis of postoperative complications after esophagectomy for 
esophageal cancer in patients recieving neoadjuvant therapy. Japanese 
Journal of Thoracic and Cardiovascular Surgery, 1999. 47(11): p. 552-8.
60. Boyle MJ, Franceschi D, Robinson DS, Livingstone AS., Neoadjuvant therapy 
for esophageal cancer: standard of care or elusive myth? American Surgeon, 
2001. 67(10): p. 956-65.
61. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J,
Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA., Chemotherapy 
followed by surgery compared with surgery alone for localised esophageal 
cancer. New England Journal of Medicine, 1998. 339(27): p. 1979-84.
62. Ishada K, Koeda K, Sato N, Ikeda K, Ohtuska K, Aoki K, Kimura Y, Iwaya T, 
Uesugi N, Nakamura R., Problems in neoadjuvant chemoradiotherapy 
preceeding surgery for advanced squamous cell carcinoma of the thoracic 
oesophagus. Japanese Journal of Thoracic and Cardiovascular Surgery, 1999. 
47(6): p. 262-6.
63. Liedman B, Johnsson E, Merke C, Ruth M, Lundell L., Preoperative adjuvant 
radiochemotherapy may increase the risk in patients undergoing 
thoracoabdominal esophageal resections. Digestive Surgery, 2001. 18(3): p. 
169-75.
64. Doty JR, Salazar JD, Forastiere AA, Heath El, Kleinberg L, Heitmiller RF., 
Pastesophagectomy morbidity, mortality, and length of hospital stay after 
preoperative chemoradiation therapy. Annals of Thoracic Surgery, 2002. 
74(1): p. 227-31.
65. Tabira Y, Okuma T, Kondo K, Yoshioka M, Mod T, Tanaka M, Kitamura N., 
Does neoadjuvant chemotherapy for carcinoma in the thoracic oesophagus 
increase postoperative morbidity? Japanese Journal of Thoracic and 
Cardiovascular Surgery, 1999. 47(8): p. 361-7.
66. Koester SK, Bolton WE, Differentiation and Assessment of cell Death. Clin 
Chem Lab Med, 1999. 37(3): p. 311-317.
67. Van Cruchten S, Van de Broek W, Morphological and Biochemical Aspects of 
Apoptosis, Oncosts, and Necrosis. Anat. Histol. Embryol,, 2002. 31: p. 214- 
223.
68. Majno G, Joris I, Apoptosis, Oncosis, and Necrosis. An Overview of Cell 
Death. Americal Journal of Pathology, 1995. 146(1): p. 3-15.
69. Miyashita T, Reed JC, Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell, 1995. 80(2): p. 293-9.
105
70. Miyashita T, Harigari M, Hanada M, Reed JC., Identification of a p53-
dependent negative response element in the bcl-2 gene. Cancer Research, 
1994. 54(12): p. 3131-5.
71. Schaper J, Kostin S, Cell Death, andAdenosine Triphosphate. Circulation, 
2005. 112: p. 6-8.
72. Katada N, Hinder RA, Smyrk TC, et al, Apoptosis is inhibited early in the
dysplasia-carcinoma sequence of Barren's oesophagus. Arch Surg, 1997. 132: 
p. 728-33.
73. Rioux-Leclercq N, Turlin B, Sutherland F, et al, Analysis ofKi-67, p53, and 
Bcl-2 expression in the dysplasia-carcinoma sequence ofBarrett's 
oesophagus. Oncol Rep, 1999. 6: p. 877-82.
74. Bennett WP, Hollstein MP, He A, Zhu SM, Resau JH, Trump BF, Metcalf 
RA, Welsh JA, Midgley C, Lane DP., Archival analysis ofp53 genetic and 
protein alterations in Chinese esophageal cancer. Oncogene, 1991. 6(10): p. 
1779-84.
75. Yang B, Rice TW, Adelstein DJ, Rybicki LA, Goldblum JR., Overexpression 
ofp53 protein associates decreased response to chemoradiotherapy in 
patients with esophageal carcinoma. Modern Pathology, 1999. 12(3): p. 251- 
6.
76. Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, Kitahara T, 
Mitamura K., Prognostic value ofp53 mutations in patients with locally 
advanced esophageal carcinoma treated with definitive chemoradiotherapy. 
Journal of Gastroenterology, 2001. 36(5): p. 303-11.
77. Matsubara H, Kimura M, Sugaya M, Koide Gunji Y, Takegana K, Asano T,
Ochiai T, Isono K, Sakiyama S, Tagawa M., Expression of"wild-type p53 gene 
confers increased sensitivity to radiation and chemotherapeutic agents in 
human esophageal carcinoma cells. International Journal of Oncology, 1999. 
14(6): p. 1081-5.
78. Krajewski S, Bloomqvist C, Franssila K, Krajewska M, Wasenius VM,
Niskanen E, Nordling S, Reed JC., Reduced expression ofproapoptotic gene 
BAXis associated with poor response rates to combination chemotherapy and 
shorter survival in women with metastatic breast adenocarcinoma. Cancer 
Research, 1995. 55(19): p. 4471-8.
79. Ikeguchi M, Maeta M, Kaibara N., Bax expression as a prognostic marker of 
postoperative chemoradiotherapy for patients with esophageal cancer. 
International Journal of Molecular Medicine, 2001. 7(4): p. 413-7.
80. Raouf A, Evoy D, Carton E, Mulligan E, Griffin M, Sweeney E, Reynolds 
JV., Spontaneous and inducible apoptosis in oesophageal adenocarcinoma. 
British Journal of Cancer, 2001. 85(11): p. 1781-6.
106
81. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE., Expression of 
apoptosis-regulating proteins and outcome ofesophageal cancer patients 
treated by combined therapy modalities. Clinical Cancer Research, 1998. 
4(12): p. 2991-7.
82. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N., bcl-2/bax ratio 
as a predictive marker for therapeutic response to radiotherapy in patients 
with prostate cancer. Urology, 1998. 52(6): p. 1085-90.
83. Shimoji H, Miyazato H, Nakachi A, Kuniyoshi S, Isa T, Shiraishi M, Muto Y, 
Toda T., Expression ofp53, bcl-2, and box as predictors of response to 
radiotherapy in esophageal cancer. Diseases of the Esophagus, 2000. 13(3): p. 
185-90.
84. Kouzu T, Suzuki Y, Yoshimura S, Yoshimura N, Hishikawa E, Arima M.,
Feature of screening-detected cancer and progress of treatment—esophageal 
cancer. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy], 
1998. 25(10): p. 1499-504.
85. Eckardt VF, Kanzler G, Bernhard G., Life expectancy and cancer risk in
patients with Barrett's esophagus: a prospective controlled investigation. Am 
J Med, 2001. 111(1): p. 33-7.
86. Kumar P, Clark M, Clinical Medicine. 1994: Bailliere Tindall. 185.
87. Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH., A majority of 
patients with Barrett's oesophagus are unlikely to benefit from endoscopic 
cancer surveillance {comment]. European Journal of Gastroenterology & 
Hepatology, 2001. 13(6): p. 639-45.
88. Rana PS, Johnston D, Incidence of adenocarcinoma and mortality in patients 
with Barrett's oesophagus diagnosed between 1976 and 1986: implications for 
endoscopic surveillance. Diseases of the Esophagus, 2000. 13(1): p. 28-31.
89. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA., Surveillance and 
survival in Barrett's adenocarcinomas: a populaton-based study. 
Gastroenterology, 2002. 122(3): p. 633-40.
90. Streitz JM Jr, Ellis FH Jr, Tilden RL, Erickson RV., Endoscopic surveillance 
of Barrett's esophagus: a cost-effectiveness comparison with mammographic 
surveillance for breast cancer. American Journal of Gastroenterology, 1998. 
93(6): p. 911-5.
91. Provenzale D, Scmitt C, Wong JB., Barrett's esophagus: a new look at
surveillance based on emerging estimates of cancer risk. American Journal of 
Gastroenterology, 1999. 94(8): p. 2043-53.
107
92. van Sandick JW, van Lanschott JJ, Kuiken BW, Tytgat GN., Impact of
endoscopic biopsy surveillance of Barren's oesophagus on pathological stage 
and clinical outcome of Barren's carcinoma. Gut, 1998. 43(2): p. 216-22.
93. Gromadzinska J, Wasowicz W, The role of reactive oxygen species in the
development of malignancies. International Journal of Occupational Medicine 
& Environmental Health, 2000. 13(3): p. 233-45.
94. Ames B, DNA damage from micronutrient deficiency is likely to be a major 
cause of cancer. Mutation Research, 2001. 475: p. 7-20.
95. Burk RF, Levander OA, Nutrition in Health and Disease, ed. OJ. Shils M, 
Shike M, Ross AC, eds. 1999.
96. Function of Selenium, Linus Pauling Institute, Micronutrient Information 
Centre.
97. Rayman M, The importance of selenium to human health. Lancet, 2000. 
356(9225): p. 233-241.
98. Mustacich D, Powis G, Thioredoxin reductase. Biochem J, 2000. 346(1): p. 1- 
8.
99. Holben DH, Smith AM, The diverse role of selenium within selenoproteins: a 
review. J Am Diet Assoc, 1999. 999(7): p. 836-843.
100. Micronutient Information Centre. 2003, Linus Pauling Institute.
101. Cousins R, Zinc. Present Knowledge in Nutrition., ed. E.E.F. Ziegler, L.J. 
1996, Washington D.C.:: ILSI Press. 293-306.
102. Dietary reference intakes for vitamin A, vitamin K, boron, chromium, copper, 
iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. 
2001, Institute of Medicine: Washington, D.C. p. 12-1-47.
103. O'Dell BL, Role of zinc in plasma membrane function. Journal of Nutrition, 
2000. 130: p. 1432S-1436S.
104. Truong-Tran AQ, Ho LH, Chai F, Zalewski PD, Cellular zinc fluxes and the 
regulation of apoptosis/gene-directed cell death. Journal of Nutrition, 2000. 
130: p. 1459S-1466S.
105. Linder MC, Hazegh-Azam M, Copper biochemistry and molecular biology. 
Am J ClinNutr, 1996. 63(5): p. 797S-811S.
106. Uauy R, Olivares M, Gonzalez M., Essentiality of copper in humans. Am J 
Clin Nutr, 1998. 67(5 Suppl): p. 952S-959S.
107. Turnlund, Copper. 9th ed ed. Nutrition in Health and Disease, ed. OJ. Shils 
M, Shike M, Ross AC, eds. 1999, Baltimore:: Williams & Wilkins.
108
108. Traber M, Utilization of vitamin E. Biofactors, 1999. 10(2-3): p. 115-120.
109. Traber M, Vitamin E. 9th ed ed. Nutrition in Health and Disease, ed. OJ. Shils 
M, Shike M, Ross AC, eds. 1999, Baltimore: Williams & Wilkins.
110. Sokol, Vitamin E. 7th ed ed. Present Knowledge in Nutrition, ed. F.L. Ziegler 
EE, eds. 1996: ILSI Press.
111. Carr AC, Frei B, Toward a new recommended dietary allowance for vitamin C 
based on antioxidant and health effects in humans. Am J Clin Nutr, 1999. 
69(6): p. 1086-1109.
112. Simon JA, Hudes ES, Serum ascorbic acid and gallbladder disease
prevalence among US adults: the Third National Health and Nutrition 
Examination Survey (NHANES III). Arch Intern Med, 2000. 160(7): p. 931- 
936.
113. Groff, Advanced Nutrition and Human Metabolism. 1995, St Paul: West 
Publishing.
114. Semba, The role of vitamin A and related retinoids in immune function. Nutr 
Rev, 1998. 56(1 Pt 2): p. S38-48.
115. Semba, Impact of vitamin A on immunity and infection in developing
countries. 2nd ed ed. Preventive Nutrition: The Comprehensive Guide for 
Health Professionals, ed. D.R. Bendich A. 2001, Totowa: Humana Press Inc.
116. Semba, Vitamin A and human immunodeficiency virus infection. Proc Nutr 
Soc, 1997. 56(1B): p. 459-469.
117. Haggitt, Barren's esophagus, dysplasia, andadenocarcinoma. Human 
Pathology, 1994. 25: p. 982-993.
118. Giminez A, Minguela A, Parilla P, Bermejo J, Perez D et al, Flow cytometric 
DNA analysis andp53 expression show a good correlation with histologic 
findings in patients with BArrett's esophagus. Cancer, 1998. 83: p. 641-651.
119. Matsumoto Y, Arai N, Mieno H, Murakami K, Ishii K, Mitomi H.,
Adenocarcinoma complicating Barrett's esophagus: an analysis of cell 
proliferation. Journal of Gastroenterology, 2001. 36(6): p. 410-4.
120. Fujii T, Nakagawa S, Hanzawa M, Sueyoshi S, Fujita H, Shirouzu K, Yamana 
H., Immunohistological study of cell cycle-related factors, oncogene 
expression, and cell proliferation in adenocarcinoma developed in Barrett's 
esophagus. Oncology Reports, 2003. 10(2): p. 427-31.
121. The Cell Cycle and Mitosis Tutorial. 1997, The University of Arizona.
109
122. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS., Barren's oesophagus:
correlation between flow cytometry and histology in detecton of patients at 
risk for adenocarcinoma. Gastroenterology, 1987. 93: p. 1-11.
123. Moe GL, Kristal AR Levine DS, Vaughan TL, Reid BJ., Waist-to-hip ratio,
weight gain, and dietary and serum selenium are associated -with DNA content 
flow cytometry in Barren's esophagus. Nutrition and Cancer, 2000. 36(1): p.
124. Lee JS, Oh TY, Ahn BO, Cho H, Kirn WB, Kirn YB, Surh YJ, Kirn HJ, Hahm 
KB., Involvement ofoxidative stress in experimentally induced reflux 
oesophagitis and Barren's oesophagus: clue for the chemoprevention of 
esophageal adenocarcinoma by antioxidants. Journal of Mutation Research, 
2000. 480-481: p. 189-200.
125. Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, 
Prevo LJ, Sanchez CA, Rabinovitch PS., Serum selenium levels in relation to 
markers of neoplastic progression among persons with Barren's esophagus. 
Journal of the National Cancer Institute, 2003. 95(10): p. 750-7.
126. Ahlbom H, Simple achlorhydric anaemia, Plummer -Vinson syndrome, and 
carcinoma of the mouth pharynx and oesophagus in women. Br J Med, 1936. 
14: p. 331-3.
127. Mayne ST, Navarre SA, Diet, Obesity and reflux in the aetiology of
adenocaarcinomas of the oesophagus and gastric cardia in humans. J Nutr,
2002. 123(11 Suppl): p. 3467S-3470S.
128. Bosetti C, Gallus S, Trichopoulou A, Talamini R, Franceschi S, Negri E, La 
Vecchia C., Influence of the Mediterranean diet on the risk of cancers of the 
upper aerodigestive tract. Cancer Epidemiology, Biomarkers & Prevention,
2003. 12(10): p. 1091-4.
129. Galeone C, Pelluchi C, Talamini R, Levi F, Bosetti C, Negru E, Franceschi S, 
La Vecchia C., Role of fried foods and oral/pharyngeal and oesophageal 
cancers. Br J Cancer, 2005. 92(11): p. 2065-9.
130. Gonzalez et.al, Meat intake and risk of stomach and oesophageal
adenocarcinoma within the European Prospective Investigation Into Cancer 
and Nutrition. J Natl Cancer Inst, 2006. 98(5): p. 345-54.
131. Gammon MD, Schoenberg J, Ahsan H, Risen HA, Vaughan TL, Chow WH, 
West AB, Rotterdam H, Dubrow R, Stanford JL, Mayne ST, Farrow DC, 
Niwa S, Blot WJ, Fraumeni JF Jr., Tobacco, alcohol, and socioeconomic 
status and adenocarcinomas of the esophagus and gastric cardia. Journal of 
the National Cancer Institute, 1997. 89(17): p. 1277-84.
110
132. Burguera JL, Villasmil L, Burguera M, Carrero P, Rondon C, de Abel de la 
Cruz AM, Brunette MR, Gallignani M, Gastric tissue selenium levels in 
healthy persons, cancer and non-cancer patients with different kinds of 
mucosal damage. Journal of Trace Elements in Medicine & Biology, 1995. 
9(3): p. 160-4.
133. Clark LC, Coombes GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis 
LS, Graham GF, Glover RA, Gross EG, Krongrad A, Lesher JL Jr, Park HK, 
Sanders BB Jr. Smith CL, Taylor JR., Effects of selenium supplementation for 
cancer prevention in patients with carcinoma of the skin. A randomized 
controlled trial. Nutritional Prevention of Cancer Study Group. Jama, 1996. 
276(24): p. 1957-63.
134. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH,
Fischbach LA, Marshall JR, Clark LC., Baseline characteristics and the effect 
of selenium supplementation on cancer incidence in a randomized clinical 
trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer 
Epidemiology, Biomarkers & Prevention, 1997. 11(7): p. 630-9.
135. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Marshall JR,. 
Selenium Supplementation and lung cancer incidence: an update of the 
nutritional prevention of cancer trial. Cancer Epidemiology Bionarkers Prev, 
2002. 11(11): p. 1285-91.
136. Knekt P, Marniemi.J, Teppo L, Heliovaara M, Aromaa A., Is low selenium
status a risk factor for lung cancer? American Journal of Epidemiology, 1998. 
148(10): p. 975-82.
137. Hoekstra W, Biochemical function of selenium and it's relation to Vitamin E. 
Fed Proc, 1975. 34: p. 2083-9.
138. Hartman TJ, Taylor PR, Alfthan G, Fagerstrom R, Virtamo J, Mark SD,
Virtanen M, Barrett MJ, Albanes D., ToenaiI selenium concentration and lung 
cancer in male smokers (Finland). Cancer Causes & Control, 2002. 13(10): p. 
923-8.
139. Zeegers MPA , Goldbohm RA, Bode P , Brant PA., Prediagnostic Toenail 
Selenium and Risk of of Bladder Cancer. Cancer Epidemiology, Biomarkers 
and Prevention, 2002. 11: p. 1292-1297.
140. Michaud DS, Hartman TJ, Taylor PR , Pietinen P , Alfthan G , Virtamo J 
Albanes D, No Association Between Toenail Selenium Levels and Bladder 
Cancer Risk. Cancer Epidemiology, Biomarkers and Prevention, 2002. 11: p. 
1505-1506.
141. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, 
Rosner B, Speizer FE, Willett WC, Hunter DJ, Prospective study oftoenail 
selenium 'levels and cancer among women. Journal of the National Cancer 
Institute, 1995. 87(7): p. 497-505.
Ill
142. Russo MW, M.S., Wurzelmann JI, Woosley JT, Sandier RS., Plasma selenium 
levels and the risk ofcolorectal adenomas. Nutrition & Cancer, 1997. 28(2): p. 
125-9.
143. Vogt M5 Ziegler RJ, Graubard BI, Swanson CA, Greenberg RS, Schoenberg 
JB, Swanson GM, Hayes RB, Mayne ST., Serum selenium and risk of prostate 
cancer in U.S. blacks and whites. International Journal of Cancer, 2003. 
103(5): p. 664-70.
144. Krishnaswamy K, Prasad MP, Krishna TP, Annapurna W, Reddy GA., A 
case study of nutrient intervention of oral precancerous lesions in India. 
European Journal of Cancer. Part B, Oral Oncology. 3 IB, 1995. 1: p. 41-8.
145. Clark L, Selenium in forage crops and cancer mortality in US countries. Arch 
Environ Health, 1991. 46: p. 37-42.
146. Shamberger R, The genotoxicity of selenium. Mutation Research, 1985. 
154(1): p. 29-48.
147. Fleet, Dietary Selenium Repetion May Reduce Cancer Incidence in People at 
High Risk Who Live in Areas with Low Soil Selenium. Nutrition Reveiws, 
1997. July: p. 277-279.
148. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, 
Kramer AM, Lotan R, Peters LJ., Prevention of second primary tumors with 
isotretinoin in squamous-cell carcinoma of the head and neck[comment]. New 
England Journal of Medicine, 1990. 323(12): p. 795-801.
149. Heimburger DC, Alexander CB, Birch R, Butterworth CE Jr, Bailey WC,
Krumdieck CL., Improvement in bronchial squamous metaplasia in smokers 
treated withfolate and vitamin B12. Report of a preliminary randomized, 
double-blind intervention trial[erratum appears in JAMA 1988 Jun 
27;259(23):3410]. Jama, 1988. 259(10): p. 1525-30.
150. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N, 
Clerici M, Soresi E, Valente M., Adjuvant treatment of stage I lung cancer 
with high-dose vitamin A.[comment]. Journal of Clinical Oncology, 1993. 
11(7): p. 1216-22.
151. Hartman TJ, Woodson K, Stolzenberg-Solomon R, Virtamo J, Selhub J,
Barrett MJ, Albanes D., Association of the B-vitamins pyridoxal 5'-phosphate 
(B(6)), B(12), andfolate with lung cancer risk in older men. American Journal 
of Epidemiology, 2001. 153(7): p. 688-94.
152. McKeown-Eyssen G, Holloway C, Jazmaji V, Bright-See E, Dion P, Bruce 
WR., A randomized trial of vitamins C and E in the prevention of recurrence 
ofcolorectal polyps. Cancer Research, 1988. 48(16): p. 4701-5.
112
153. Ponz de Leon M, Roncucci L, Chemoprevention ofcolorectal tumors: role of 
lactulose and of other agents. Scandinavian Journal of Gastroenterology 
Supplement, 1997. 222: p. 72-5.
154. Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, Blot WJ., Prevention 
ofesophageal cancer: the nutrition intervention trials in Linxian, China. 
Linxian Nutrition Intervention Trials Study Group. Cancer Research, 1994. 
54(7 Suppl): p. 2029s-2031s.
155. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR,
Belanger C, LaMotte F, Gaziano JM, and W.W. Ridker PM, Peto R., Lack of 
effect of long-term supplementation with beta carotene on the incidence of 
malignant neoplasms and cardiovascular disease [comment]. New England 
Journal of Medicine, 1996. 334(18): p. 1145-9.
156. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y, Laplanche 
A., Prevention of second primary tumours with etretinate in squamous cell 
carcinoma of the oral cavity and oropharynx. Results of a multicentric double- 
blind randomised study, [comment]. European Journal of Cancer 30A, 1994. 6: 
p. 767-72.
157. Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, Morice RC, 
Peters EJ, Pang AC, Fritsche HA Jr., Randomized placebo-controlled trial of 
isotretinoin in chemoprevention of bronchial squamous metaplasia. Journal of 
Clinical Oncology, 1994. 12(5): p. 937-45.
158. Arnold AM, Browman GP, Levine MN, D'Souza T, Johnstone B, Skingley P, 
Turner-Smith L, Cayco R, Booker L, Newhouse M., The effect of the synthetic 
retinoid etretinate on sputum cytology: results from a randomised trial. British 
Journal of Cancer, 1992. 65(5): p. 737-43.
159. Anonymous, The effect of vitamin E and beta carotene on the incidence of
lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta 
Carotene Cancer Prevention Study Group[comment]. New England Journal of 
Medicine, 1994. 330(15): p. 1029-35.
160. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, 
Keogh JP,.Meyskens FL, Valanis B, Williams JH, Hammar S, Barnhart S, 
Effects of a combination of beta carotene and vitamin A on lung cancer and 
cardiovascular disease, [comment]. New England Journal of Medicine, 1996. 
334(18): p. 1150-5.
161. Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr, Beck GJ, Bond JH, 
Colacchio TA, Frankl HD, Coller JA, Haile RW., A clinical trial of 
antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study 
Group [comment]. New England Journal of Medicine, 1994. 331(3): p. 141-7.
113
162. Jacobs EJ, Connell CJ, Patel AV, Chao A, Rodriguez C, Seymour J,
McCullough ML, Calle EE, Thun MJ., Multivitamin use and colon cancer 
mortality in the Cancer Prevention Study II cohort (United States). Cancer 
Causes & Control, 2001. 12(10): p. 927-34.
163. Malila N, Virtamo J, Virtanen M, Pietinen P, Albanes D, Teppo L., Dietary
and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal 
cancer in male smokers. European Journal of Clinical Nutrition, 2002. 56(7): 
p. 615-21.
164. Michaud DS, Pietinen P, Taylor PR, Virtanen M, Virtamo J, Albanes D.,
Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation 
to the risk of bladder cancer in the ATBC cohort study. British Journal of 
Cancer, 2002. 87(9): p. 960-5.
165. Munoz N, Wahrendorf J, Bang LJ, Crespi M, Thurnham DI, Day NE, Ji ZH, 
Grassi A, Yan LW, Lin LG., No effect ofriboflavine, retinol, and zinc on 
prevalence of precancerous lesions of oesophagus. Randomised double-blind 
intervention study in high-risk population of China. Lancet, 1985. 2(8447): p. 
111-4.
166. Jacobs EJ, Connell CJ, McCullough ML, Chao A, Jonas CR, Rodriguez C, 
Calle EE, Thun MJ., Vitamin C, vitamin E, and multivitamin supplement use 
and stomach cancer mortality in the Cancer Prevention Study II cohort. 
Cancer Epidemiology, Biomarkers & Prevention, 2002. 11(1): p. 35-41.
167. Guo L, Xue AN, Wang SQ, Chen JY, Wu YD, Zhang B., Induction of 
apoptosis by superoxide anion and the protective effects of selenium and 
Vitamin E. Biomedical & Environmental Sciences, 2001. 14(3): p. 241-7.
168. Abdel-Latif MM, Raouff AA, Sabra K, Kelleher D, Reynolds JV., Vitamin C 
enhances the chemosensitisation ofoesophageal cancer cells in vitro. J 
Chemother, 2005. 17(5): p. 539-49.
169. Shen ZY, Shen WY, Chen MH, Shen J, Zeng Y., Reactive oxygen species and 
antioxidants in apoptosis ofoesophageal cancer cells induced by As2O3. Int J 
Mol Med, 2003. 11(4): p. 479-84.
170. Hawker FH, Stewart PM, Smith PJ., Effects of acute illness on selenium 
status. Crit Care Med, 1990. 18: p. 442-6.
171. Caygill CPJ, Reid PI, Mclntyre A, Hill MJ., The UK National Barren's 
Oesophagus Registry: a study between two centres. European Journal of 
Cancer Prevention, 1998. 7: p. 161-164.
172. Morris-Stiff GJ, Bowrey D, Oleesky D, Davies M, Clark GWB, Puntis MCA., 
The Antioxidant Profiles of Patients with Recurrent Acute and Chronic 
Pancreatitis. American Journal of Gastroenterology, 1999. 94(8): p. 2135- 
2140.
114
173. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine 
DS, Reid BJ., Effect of segment length on risk for neoplastic progression in 
patients with Barren's esophagus. Ann Intern Med, 2000. 132(8): p. 612-20.
174. Bremner RM, Bremner CG, DeMeester TR., Gastroesophageal reflux:the use 
ofpHmonitoring. Curr Probl Surg, 1995. 32(6): p. 429-558.
175. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, 
Johnson F, Kongo M, Richter JE, Spechler SJ, Tytgat, GNJ, Wallin L., 
Endoscopic assessment ofoesophagitis: clinical and functional correlates and 
further validation of the Los Angeles classification. Gut, 1999. 45: p. 172-180.
176. Hinton P, Statistics Explained. 2004, London: Routledge.
177. Hu J, Nyren O, Wolk A, Bergstrom R, Yuen J, Adami HO, Guo L, Li H, 
Huang G, Xu X., Risk factors for oesophageal cancer in northeast China. 
International Journal of Cancer, 1994. 57(1): p. 38-46.
178. Professor B Jasani, Pathology Department, University Hospital of Wales, 
Cardiff, Personal Communication. 2006.
115
APPENDICES
Appendix I: Information sheet provided to patients recruited into study.
Project Title: A study to investigate the antioxidant profiles of patients with Barrett's oesophagus
(Version 3,14th April 2003)
Patient Information Sheet
You are being invited to take part in a research study that is being undertaken by the 
Department of Surgery, Royal Glamorgan Hospital. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends and 
relatives if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitiled 'Medical 
Research and You'. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box 1365, London, N16 OBW. Thank you for reading this
Why have I been chosen?
Your consultant has recommended that you undergo an endoscopy examination of 
your stomach, to investigate the cause of your symptoms. An endoscopy is a flexible 
camera examination of the oesophagus (gullet) and stomach. This is either performed 
with local anaesthetic spray to the back of your throat or with an injection of a 
sedative to make you sleepy. The potential risks of having an endoscopy are 
extremely small, and include bleeding or perforation (making a tear in the oesophagus 
or stomach). The risk of either of these occurring is 0.02%, that is a 1 in 5000 chance.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. You 
will keep a copy of the signed consent form. If you decide to take part, you are still 
free to withdraw at any time and without giving a reason. This will not affect the 
standard of care you receive.
What will happen to me if I take part?
As part of this research project you would be required to answer a few simple 
questions about yourself and have 15 ml of blood (1 tablespoon) taken from a vein in 
your arm or the back of your hand.
What are the side effects of taking part?
The possible side effects of taking the blood are minor pain or bruising at the site 
where the needle is inserted.
What are the possible benefits of taking part?
The information we get from this study may help us understand acid reflux disease 
better and may help us to treat future patients with this condition.
What if something goes wrong?
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then you 
may have grounds for a legal action, but you may have to pay for it. Regardless of 
this, if you wish to complain about any aspect of the way you have been approached 
or treated during the course of the study, the normal National Health Service 
complaints mechanisms may be available to you.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information which leaves the hospital will have your 
name and address removed so that you cannot be recogmised. The permission of your 
consultant has been obtained so that you can be invited to participate in the research 
study.
What will happen to the results of the research study?
We hope that the results will be available in about 18 months time and that they will 
be published in a medical journal. If you would like a copy, please let us know.
Who is organising and funding the research?
The research is not sponsored by any company or research organisation.
Who has reviewed the study?
Bro-Taf Local Research Ethics Committee have reviewed the study.
Contact for further information
Whilst taking part in our research, if you have any problems, please contact Mr D.J. 
Bowrey or Mr TJ. Havard, Department of Surgery, Royal Glamorgan Hospital by 
telephoning 01443-443542.
Project Title: A study to investigate the antioxidant profiles of patients with Barrett's oesophagus
(Version 3, 14th April 2003)
I have read the Patient Information Sheets and agree to participate in the study. 
The nature of the study has been fully explained to me by:________________ 
Signature of responsible physician:_________________ 
Name of patient:__________________ 
Signature of patient:_____________________
Signature witnessed by (name):
Signature of witness:_________________ Date:






























































































































































I/ If II II II II III! ii ti ti i) mi fitt'
it II it II II II it It 
fillililtttlli#
It It It II II It l!#
TT'TT II it ff-ff It It-




II II It II It II II II
lltfHIIIIIIIIft 
11 U U I! It 11 Hit-
II II 11 Hll II lltl
it n n till u nit
n n mi mi nit
iiiiinniiiiiii
n tt n a n n ti n
n ii n it ii ii ii it
# !! 11 It It 1! IS ffii nun mi it
an n n 11 n n it
it an it n n n it
it 11 n ii n 11 mi
n nti it n a it it
it nit n it n n a
it mi n it n n n
n unit tut tut






11 tilt 11 tltltll^
m'uiiiiinit
tf U fl ff //// // //
II II II II II II II ft
JUI It till II Hit
inittiiiniini
////////////////
ii it n it ii 11 utt
ll-ll II 11 HHIIIf^
Illllllllllllllt





































































































II II II Hll II lf# 
II 11 lit! 11 It lilt 
II II II till !i II It 
11 11 It II till It tt 
Illllllllllllllt
(tint ii it Hint
it mi tut 1111 ii 
nit ii ii inin ti- 
ll n nit H till it 
tiiiiiiiiiiinit 
n 11 tut ii ii n it
It II II It II It Hit
n n nun n nit
n ii 'it it ii 'ii u it
n it ii ii n n ii it
it n n n it nit tt
ti it mi tin n n
n nn n mi n it
IliltllllllllHI





mi tut mi ti it




nit n n mi nit
iiiiiiiiiiiiiiii
II II 11 till II II It
iiiiiiiiniiiiit
I! II It It II II It fi-
G H
Type Study Groi
Out patient Normal Co 
Out patient Reflux, no 
Out patient Normal Co 
Out patient Normal Co 
Out patient Normal Co 
Open Acce Reflux, no
Out patient Normal Co 
Open Acce Normal Co 
Open Acce Barrett's(s) 
Open Acce. Reflux, no 
Open Acce Normal Co 
Open Acce Reflux, no 
Open Acce Reflux, no
Open Acce Normal Co






















Out patient Normal Col TRUE
Out patient Barrett's(s) TRUE
Out patient} Reflux, no | TRUE
In-patient Barrett's(s]
Open Acce Reflux, no
Open Acce, Normal Co
Open Acce Reflux, no
Open Acce Normal Co
Open Acce Reflux, no
Open Acce Normal Co
In-patient Normal Co
Out patientj Normal Co















Open Acce Barrett's(s)! FALSE
Out patient! Barrett's(sl
Out patient Normal Co
ll II II II 11 11 II It- Open Acce Normal Co
Illllllllllllllt Out patient Barrett's(s]
Illlll II Illl II It Open Acce Reflux, no
llllllllllllllll Open Acce Reflux, no
######## Open Acce1 Normal Co










IIIIUHJUI Hit] Male 51
nn ii ii ii n nn-




Open Acce Reflux, no
Open Acce Reflux, no
Open Acce, Reflux, no
Open Acce, Normal Co
Open Acce Normal Co
Out patient Barrett's(s)
till II II It It It II \O\j( palienl BaiieU's(s)
II II fill ft It It It
II I Hi II II 11 Illi
















Out patient Barrett's(s) FALSE
Open Acce Reflux, no TRUE
Open Acce Normal Co| FALSE
Out patient Barrett's(s) TRUE




















































































































































n n ii it ttn tut 
ii it n it n ii ii it
It II II II I! II It It 
11 II It 11 llll II ti-
ll II It II II lilt tt
II Illl II nil nil
11 II II II 11 II II 11
II II It 'It till It fi-
ll II II It II II It tt
tut tin nit ntt
n it n n n n n #
n n n mi n n it-
II II It II II II II II--
II II II II It It II !!  
II II II II II II II 'It
II II II II II II II tt
IllllllllllllUt
II II II II II II It It
II If II It II II It tt
II II II II II II II tt
it II II II II II lift
II 11 III! II It II It
II IHI It II II II It-
11 II II II II II II It
II II II II II II lift
II II II II II II II ft
till II II II II II ft
II II II II II 11 II ft
II II II II II II II ft
II II II It It II lift








































































II II II II II II 11 II Female 60
IllllllllllllUt Male 73
11 It II Sill It II It Female 56
11 II It II II II Illl Male 35
11 II II II II II II II Female 54
II It nttll II tilt Male 67
Illlllllllllllll Male 66
 tlti II lilt II II II Male
11 It Illl II mill Male
57
61






UK !!ll 11 II IS 11 Male
11 It 11 IS 11 11 II It^
it II 11 11 11 II II If
11 II II II II 11 II It







M2027663 11 II II II 11 II III? Mate 44
F
II II II II II II II It- 
It II II It II II lilt 
IllllllllllllUt 
II II II 1! II II It II 





mi ii ii ii ti mi
II iHI It II till It
tin n it ntt tut
IllllllllllllUt
n ii ii mi it nit
it n n tut n mi
it n n it n n nit
niiiiiiniinii
n n it n n it tin
n n n tin n n n
II tilt till It till
mi ii n n tut n
it n n mi n ntt
n n n mi n tut





























































Open Accej Barrett's(s) FALSE
Open Acce i Reflux, no
Open Acce| Normal Co
Open Acce Normal Co
Open Acce Normal Co
Open Acce Reflux, no







II II till II II II II Open Acce Normal Co| TRUE
ii ii mi ii mi ft
ii n ii mi tin ft
IlllltlUIIUIft
Ill/IUI/IIUtit
n n n n n mi ft
tut it tin n ntt
ii mi mi a n n
nn 11 ins si mi
Open Acce Barrett's(s)1 FALSE








Open Acce Barrett's(s) TRUE
Out patient Barrett's(s)' TRUE
Out patient; Barrett's(s)
Out patient Barrett's(s)
II Illl II II II ft# Open Acce; Reflux, no
II II II II II II lf#
II II II II till II ft
########
Open Acce Reflux, no
Open Acce Reflux, no
Out patient











II II II II Illl It II Out patient Barretfs(s) FALSEIlllllllllllllll ' ' ...-.-
Illl II 111! II II II
nun ii ii ii ttit
Out patient Barrett's(s) FALSE









//#•//////////// 1 Open Acce Normal Co







Illlllllllllllll- Out patient Barretf s(s) FALSE
fttttfll II fUlll ', Open Acce barren s(s) I KUt






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FALSE 0 0 0
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TRUE 1 39 7


























































































































































































































































































































Appendix III: Publication and Presentation of Data. 
DATA FROM CHAPTER THREE
Clements DM, Oleesky DA, Smith SC, Wheatley H, Hullin DA, Havard TJ, Bowrey
DJ.
A study to determine plasma antioxidant concentrations in patients with Barrett's
oesophagus.
J Clin Pathol 2005;58:490-492.
Clements DM, Oleesky DA, Smith SC, Wheatley HL, Hullin D, Havard TJ, Bowrey,
DJ.
A study to determine serum antioxidant levels in patients with Barrett's oesophagus.
Presented by Mr. Bowrey at Society of Academic and Research Surgery.
Association of Upper GI Surgeons Symposium. Newcastle 2005.
Presented by myself at South Wales Gut Club April 2005.
